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ABSTRACT
The potential of human embryonic stem cells (hESCs) to differentiate into insulin
producing β cells offers great hope for cell-based therapy for diabetes treatment. However, in
vitro pancreatic differentiation of hESCs remains challenging. In the past decade, most protocols
for differentiating pancreatic cells have been focused on the use of signaling molecule cocktails
on 2D substrates. Studies on embryonic development biology strongly suggest that extracellular
matrix (ECM) plays a critical role on hESCs behavior. In this work, we first established a 3D
collagen scaffold culture system for hESCs differentiating into definitive endoderm (DE), which
is the first and most important step for coaxing hESCs into transplantable β cells. Collagen
scaffold have shown to promote the attachment, proliferation and DE differentiation of hESCs in
3D microenvironment. Furthermore, we optimized the 3D scaffold compositions by integrating
various ECM proteins into collagen scaffold. Our data showed that compared to collagen with
single ECM protein, collagen combined with fibronectin, laminin, and vitronectin can greatly
enhance DE differentiation generating up to 93% SOX17 positive DE population. Finally, we
demonstrated that mature insulin-producing cells can be achieved by differentiating hESCs in 3D
biomimic scaffold made of collagen and Matrigel, combined with a modified step-wise protocol.
More mature insulin-producing cells were generated with our 3D scaffold compared to
traditional 2D culture. The 3D differentiated pancreatic endocrine cells were assembled into
tissue-like structure and displayed greater similarities in phenotype and gene expression profile
to adult human islets. These hESC-induced pancreatic cells comprised 20% insulin positive cells
in 3D culture and can response to high glucose and release four-fold insulin as compared to 2D
culture. Insulin-secreting granules were also observed, which confirmed the generation of
insulin-producing cells in 3D scaffold.
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CHAPTER 1
INTRODUCTION
1.1. Stem cells
Stem cells are type of cells that have the capability of self-renewal and differentiation [1].
More explicitly, stem cells can divide and generate daughter cells that are identical to their
mother cells (self-renewal), as well as give rise to other daughter cells that produce differentiated
descendants with more lineage-restricted potential (differentiation). There are three basic types
of stem cells: embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), and adult
stem cells (ASCs). Tremendous attentions and interests have been directed toward research in
the area of stem cells, owing to their unique properties. By understanding stem cells, it will offer
insight into the biology of cells as well as a path for cell replacement and transplantation therapy.

1.1.1 Embryonic stem cells
Shortly after fertilization, mammalian embryos undergo a series of divisions to form the
morula, a solid ball-like aggregate of totipotent cells which, if isolated, have the ability to
develop into a complete organism [2, 3]. Further cell divisions convert morula into a blastocyst, a
cystlike structure with an inner cavity surrounded by cells. The cells of outer layer of blastocyst
differentiate into the trophoblast that eventually become the placenta and sustains nutrient supply
to the embryo. In contrast, the cells of inner layer, called inner cell mass (ICM), which remain
pluripotent and are capable of extensive, perhaps unlimited, self-renewal, ultimately develop into
the fetus. In 1981, similar work by Martin Evans and Matthew Kaufman as well as Gail Martin
showed that mouse embryos can be cultured in vitro and ICM cells can be isolated from these
1

embryos and cultured outside the body without losing their pluripotency [4, 5]. These cultured
cells were then named as embryonic stem cells (ESCs). In 1998, Thomson et al. developed a
technique to isolate and grow human embryonic stem cells (hESCs) in vitro [6]. The isolation of
stable hESCs from donated, otherwise discarded, human blastocysts, therefore, creates a
potentially unlimited source of any human cell types, and thus sets the stage for cell replacement
therapy. hESCs hold enormous promising for understanding development of many diseases as
well as for treating devastating and currently incurable disorders such as spinal cord injury,
neurological disease, blindness and type 1 diabetes.

1.1.2 Adult stem cells
Adult stem cells, also called somatic stem cells, are undifferentiated cells that reside in
developed tissues of juvenile as well as adult bodies. Adult stem cells have the ability of
indefinite self-renewal, so they can divide regularly to replenish dying cells and to regenerate
damaged tissues. Unlike ES cells, the differentiation ability of adult stem cells are more lineagerestricted, i.e. they can only generate progeny of several distinct cell types, which related to their
tissue origin (multipotency), as opposed to the pluripotency of ES cells. Adult stem cells have
been found in blood, brain, muscle, skin, bone etc.
Adult stem cells have been successfully used for disease treatment for many years. Bone
marrow transplantation has been approved for patients with inherited blood disorder, blood
cancers such as lymphoma and leukemia, or who are undergoing chemotherapy or radiotherapy.
Autologous hematopoietic stem cells (HSCs) have been successfully applied to treat spinal cord
injury [7], liver cirrhosis [8] and peripheral vascular ischemia [9]. Mesenchymal stem cells

2

(MSCs) have been used in the treatment of patients with osteogenesis imperfect, infarcted
myocardium, or joint disease [10-12]. Neural stem cells (NSCs) can differentiate to neurons,
astrocytes and oligodentrocytes and have been used in a number of clinical trials for
neurometabolic and neurodegenerative diseases like Parkinson’s disease [13, 14]. Although the
use of adult stem cells in research and therapy is not considered to be controversial, these cells
may not be as versatile and durable as ESCs. First, adult stem cells are rare in adult tissues and
are difficult to isolate and maintain in vitro. Also, their proliferation potential is not comparable
to ESCs, so harvesting and culturing them up to scale for clinic purpose remains challenge.
Second, adult stem cells are not able to produce all cell types, limiting their use in disease
treatment. Furthermore, they are more likely to contain abnormalities due to environmental
hazards, such as toxins, or from cell replication error.

1.1.3 Induced pluripotent stem cells (iPSCs)
In 2006, Dr. Yamanaka made a breakthrough discovery that through retroviral
transfection of a defined set of transcription factors (Oct3/4, Sox2, c-Myc, and Klf4), adult
somatic cells can be genetically reprogrammed into cells which have pluripotent capability and
behave equivalent to ESCs, termed as induced pluripotent stem cells (iPSCs) [15]. This
discovery has made Yamanaka won the Noble Prize in Physiology or Medicine in 2012. To date,
iPSCs have been successfully generated from multiple types of human somatic cells, including
fibroblasts [16-18], blood cells [19], neural progenitors [20], and terminally differentiated mature
B lymphocytes [21]. Also, as alternatives to potentially harmful retroviruses strategy, multiple
approaches have been proposed to generate iPSCs, including virus-free transposonsystem [22],
mimicking transcription factors with small-molecule compounds [23-25], drug-inducible systems
3

[26, 27], recombinant proteins [28, 29]and microRNAs [30, 31]. The high degree of similarity
between iPSCs and ESCs has been confirmed on many levels, such as the expression of certain
stem cell genes and proteins, in vitro differentiation analysis, teratoma formation [15, 16, 18],
epigenetic studies [32], and tetraploid complementation [33, 34]. The development of iPSCs
allows researchers to obtain patient-specific iPSCs that are theoretically tolerant to immune
rejection. Thus, the development of iPSC technology has provided a powerful tool for
biomedical research and widened the era of hope for patient-specific cell therapy, drug discovery,
and disease modeling.
However, the potential clinical application of iPSCs remains some limitations. First, the
use of viruses for inducing iPSCs could potentially introduce cancers, which is considered a
major obstacle to stem cell based regenerative medicine. Furthermore, although many
similarities between ESCs and iPSCs, several studies have shown that these two pluripotent cell
types display significant differences. A study of gene expression profile of mouse and human
ESCs and iPSCs revealed that a recurrent gene expression signature appeared in iPSCs
regardless of their origin or the method by which they were generated [35]. Also, reprogrammed
iPSCs retained an epigenetic memory from their parental cells of origin, which directed iPSCs
favor their differentiation along lineages related to the donor cells, while restricting alternative
cell fates [36]. Meissen, J. K. et al. demonstrated that iPSCs showed metabolomic differences to
ESCs, specifically for amino acids metabolism [37]. Also, a recent study reported that teratomas
formed by iPSCs were mostly immune-rejected by recipients, which challenged the assumption
of immunogenicity of iPSCs [38]. In addition, some studies showed iPSCs possess some
somatic coding mutations of currently unknown functions [39-41].
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1. 2. Current and future therapies for diabetes mellitus
Insulin-secreting pancreatic β-cells are important for regulating mammalian metabolism.
The deficiency of β-cell functions leads to diabetes, making patients suffer from hyperglycemia
and mainly dependent on exogenously supply of insulin. Generating new functional β-cells
would provide unprecedented opportunities for diabetes treatment. Based on the progressed
understanding on β-cell development and the discovery of pluripotent stem cells, tremendous
progress has been made to generate new pancreatic β-cells, including discovering and improving
conditions that promote β-cell replication in vivo and in vitro, differentiating pluripotent stem
cells into insulin-secreting β-cells, or converting terminally differentiated cell types into β-cells.
Here, we summarized existing technologies that have been developed for generating
physiological functioning β-cells that might be potentially used for cell transplantation for
diabetes treatment.

1.2.1. Diabetes mellitus
Diabetes mellitus is a leading metabolic disease characterized by hyperglycemia. Glucose
level in blood is basically balanced by two types of cells, pancreatic β-cells and α-cells, which
reside in pancreatic islets of Langerhans. Explicitly, increased glucose level stimulates insulin
secretion by pancreatic β-cells. Tissues such as liver and muscle will sense the signal of insulin
and take up glucose from the blood. In contrast, when glucose level drops, α-cells secret
glucagon and trigger the liver and muscles to produce glucose from stored glycogen. According
to the statistics of the 2011 National Diabetes Fact Sheet from American Diabetes Association
(ADA) (http://www.diabetes.org), 25.8 million children and adults have diabetes in the United
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States alone, which is 8.3% of the population. Also, the total cost of diagnosed diabetes was
$245 billion in the United States in 2012. Worldwide, the prevalence of all diabetes types is
increasing, and the total number of diabetes patients is estimated up to 366 million by 2030
[42].Therefore, diabetes has become a growing global health problem with a striking impact on
health, society and economy.
Diabetes is clinically classified into two major types: Type I or insulin-dependent
diabetes (T1DM), which results from destruction of insulin-secreting β cells in the pancreatic
islets of Langerhans by T cell-mediated autoimmune [43], and Type II diabetes (T2DM) or noninsulin-dependent diabetes, which develops when the body does not produce enough insulin or is
not able to use it effectively, called insulin resistance, which is often associated with obesity,
age and genetic component [44]. Insulin resistant in peripheral tissues such as fat and muscle
causes high demand on β-cells and leads to β-cell malfunction, de-differentiation and death [44].
A decrease in β cell mass of up to 60% has been reported in T2DM [45].
Since the successful isolation of biologically active insulin in the early 1920s, exogenous
insulin injection combined with blood glucose monitoring and lifestyle adaption has remained
the main treatment for diabetes. Although exogenous supply of insulin have greatly improved the
lives of diabetic patients, the method is inaccurate and was not fully capable of mimicking the
tight control of endogenously produced insulin release from pancreatic β-cells, thus cannot
completely control the minutes-to-minutes fluctuations in systemic blood glucose. Poorly
managed diabetes can lead to secondary complications including infections, cardiovascular
disease, renal disease, autonomic and peripheral neuropathy, as well as visual impairment which
can progress to blindness [46]. Therefore, in order to prevent these complications and improve
patients' life quality, more precise glycemic control is necessary. The ultimate goal of diabetes
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therapy is to restore patients' physiological insulin-secretion capability through β-cell
transplantation or regeneration.

1.2.2. Islet transplantation
Replenishing the functional β-cell mass is a commonly accepted strategy for diabetes
treatment. The Edmonton Protocol first described an effective cell replacement therapy for
T1DM [47]. Cadaveric donor islets were isolated and infused into the liver of diabetic patients
via the portal vein, in conjunction with immunosuppressive regimen. The clinical outcomes of
islet transplantation were very encouraging. The five year follow-up report from Shapiro and his
colleagues reported that about 10% of the 65 patients enrolled in the Edmonton Center study
remained insulin independence for 5 years after islet transplantation [48, 49]. The remaining
patients, although not free from insulin replacement therapy, were protected from severe
hypoglycemic episodes and diabetes-related complications. In recent data of 2010 annual report,
the Collaborative Islet Transplantation Registry (http://www.citregistry.ory) reported that about
25% of the 481 patients who received islet transplantation from 1999-2009 achieved insulin
independence for 3 years.
The Edmonton protocol presents great potential as a treatment and cure for diabetes;
however, its use has been limited by the scarcity of organs from cadaveric donors. Keymeulen et
al. showed that the initial beta cell mass transplanted should be at least 2 × 106 cells/kg body
weight in order to achieve a functioning graft and to achieve a reproducible metabolic control
[50]; thus, the treating of one diabetic patient with this approach requires more than one donor
for cell transplantation. Additionally, as islets are currently derived from cadavers, the host-graft
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immune rejection is a significant limitation to transplantation therapy. Therefore, strategies to
promote either the expansion of existing β-cells within the body or the supply of novel sources of
clinically relevant β cell alternatives, which are reliable and reproducible, are currently debated
as future treatment options.

1.2.3. In vivo regeneration of pancreatic β-cells
Inadequate β-cell mass is common to both type 1 and type 2 diabetes (T1DM, T2DM).
Recent studies using genetic lineage tracing or other cell labeling methods have shown that the
growth and regeneration of adult β-cells do not involve specialized progenitors or non-β-cells
[51-53]. In contrast, the postnatal β-cell mass are predominantly maintained via self-replication
of pre-excising β-cells rather than stem cell differentiation. In Dor et al.'s study, they labeled
pancreatic β-cells with human alkaline phosphatase by Cre-loxP-based conditional
recombination in adult pancreas, and chased the face of pre-existing β-cells. The results showed
that the labeling frequency of the β-cells remained unchanged, indicating that the new β-cells
were generated primarily from pre-existing β-cells, rather than pluripotent stem cells, during
adult life and after pancreatectomy in mice [51].
Normally, pancreatic size appears to be limited by the size of initial progenitor cell pool
that is set aside in the developing pancreatic bud during embryogenesis [54]. Human adult
pancreatic β-cells are known that they are highly specialized and have a low turnover rate due to
tight cell cycle [55-57]. However, β-cell mass is dynamic and it undergoes significant changes
under certain circumstances, including neonate, pregnancy and obesity. The pancreatic fractional
area was increased by 1.4-fold to match dynamic physiological demands [58]. There is evidence
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that circulating maternal hormones in the blood stream such as prolactin, placental lactogen can
directly regulate β-cell proliferation in pregnancy through the intracellular factor menin [59-61].
Conversely, the turnover rate of β-cells slows down with aging [62]. Kassem et al. found that
the rate of β-cell replication progressively decreased from 3% among fetal β-cells to less than 0.5%
by 6 months of age [55].The mechanism of these changes are unknown. At molecular level,
there is evidence that cyclin-dependent kinase 4 (cdk4)-cyclin D complex is required for β-cell
replication during neonatal and adult growth [63, 64]. In cyclin D-/- mice, pancreatic islets were
dramatically smaller and β-cell mass was reduced 4-fold in comparison to wild-type mice. Thus,
cycin D plays a key role in β-cell replication, which might be the primary mechanism underlying
the maintenance of postnatal β-cell mass. Furthermore, a recent study showed that EGF-receptor
signaling is essential in β-cell mass expansion in mice during high-fat diet and pregnancy [65].
These discoveries may provide a target for development of therapeutic strategies to induce the
expansion of β-cells.
Most diabetic patients, even those with long-standing T1D, have a small number of βcells that continually replicate and undergo destruction, thus giving a hope that diabetes may be
cured by preventing autoreactive β-cell destruction, and/or by supporting replication of the
surviving β-cells [66]. Therefore, screening for factors that increase β-cell replication in vivo
may have direct therapeutic benefits to diabetic patients. In vitro studies have shown that
nicotinamide, an inhibitor of poly (adenosine diphosphate-ribose) synthethase/ polymerase, has
the ability to induce proliferation and differentiation of pancreatic endocrine cells [67, 68].
Betacellulin, a growth factor of epidermal growth factor (EGF) family, has shown to promote
neogenesis of β-cells and ameliorate glucose tolerance in mice [69] and promote proliferation of
β-cells in 90% pancreatectomized rats [70]. Exendin-4, an analog of GLP-1, has shown to
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stimulate both β-cell proliferation and neogenesis in rat with 90% pancreatectomy, resulting in
increased β-cell mass and improved glucose tolerance [71]. Also, the replication-inducing effects
of exendin-4 have also been observed in human islets [72, 73]. Additional small-molecules
acting as β-cell replication regulators, including phorbol esters, thiophene-pyrimidines,
dihydropyridine derivatives and adenosine kinase inhibitors, have been identified through highthroughput screening of small molecular libraries for β-cell proliferation inducers in
immortalized β-cell lines or primary rodent islets [74, 75]. More recently, Schultz et al. identified
a novel small molecule, WS6, increased both rat and human β-cell replication in vitro by six-fold
in dispersed islets and by more than ten-fold in intact islets [76].
Promoting endogenous β-cell replication by biological signals or small molecules is a
promising treatment, but this method has not been applied for clinical application yet. A
particular risk of such a strategy is the inadvertent promotion of tumorigenesis [77]. For success,
putative molecules would have to show β-cell specificity. Also, targeted molecules would have
to be tested with regard to their effect on other cell type within the body in order to exclude
unwanted neoplastic effects. If we can find a way to harness endogenous β-cell replication
without affecting other cell types, then we might develop a new therapy for diabetic patients.

1.2.4. In vitro expansion of pancreatic β-cells
In vitro expansion of pancreatic β-cells represents an attractive strategy for obtaining a
substantial quantity of β-cells for transplantation. Studies have demonstrated that human β-cells
have the capacity of in vitro proliferation; however, it was generally agreed that human β-cells
are difficult to be expanded in culture due to their low turnover rate and loss of function easily.
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Noguchi and colleagues showed that even after culture of 48-72 hours, human islets lost half the
islet cells, as well as dramatically decreased glucose-stimulated insulin secretion (GSIS) in vitro
and a reduced ability to restore normoglycemia after transplantation into diabetic mice [78].
These studies suggested that studies that are focused on identifying in vitro conditions for
increasing the proliferative potential of adult human β-cells while maintaining their glucoseresponsive insulin secretion is critical to realizing this treatment.
A line of evidence divulges that different growth factors and hormones, including
glucagon-like peptide-1 (GLP-1), parathyroid hormone-related protein (PTHrP), lactogens,
hepatocyte growth factor (HGF), insulin, and insulin-like growth factors (IGFs) are important to
β-cell survival and maintenance of their function in vitro [79]. Additionally, several studies have
been focused on exploring pathways that drive β-cell proliferation while maintaining their
function. By using in vitro and in vivo models, the delivery of transcription factors associated
with cell cycle, such as cyclin D1 [80, 81], cyclin-dependent kinas 2 (cdk2) [82], cyclin E [82],
cdk6 [81, 83], c-Myc [84], and hepatocyte nuclear factor-4α [85], has been shown promising for
enhancing the replication of adult human β-cells and their functions in vitro. More recent study
showed Wnt/GSK-3/β-catenin and mTOR signaling pathways are necessary to stimulate growth
and proliferation of human β-cells [86, 87]. Despite the development of various strategies that
promote the replication of β cells by using growth factors or molecules, the risk of cancer after
transplantation would be particularly important to consider.
With more insights gained into the pancreas structure in the last decades, researchers
realized that another reason for the loss of β-cell functions in in vitro culture is the change of
cellular environment. Most β-cell expansion cultures are carried out based on monolayer culture,
which neglects one of the important tissue niches, i.e. extracellular microenvironment essential
11

for maintaining cell functions. In vivo, β-cells reside in a three-dimensional (3D) islet structure
and interact directly with basement membranes in fetal and adult tissues [88]. Thus, reestablishment of the islet-matrix relationship to mimic in vivo environment may present a natural
stimuli for in vitro β-cell expansion. A line of studies has showed that extracellular matrix
protects pancreatic β-cells against apoptosis and improves their insulin-secreting function [89,
90]. However, the underlying mechanism for these improvements remains elusive.
Some reports suggested that β-cells cultured in vitro can dedifferentiate through
epidermal-mesenchymal transition (EMT), a biological process in the development stage that
allows a polarized epithelial cell to go through multiple biochemical changes and assure a
mesenchymal cell phenotype and finally be directed redifferentiating into insulin-secreting βcells [91, 92]. However, the β-cell phenotype was not fully recovered, such as the new β-cells
expressed only a fraction of their original insulin levels. Moreover, the origin of these new βcells derived in this way is not clear due to a possible contamination by other pancreatic cells
which are mitotic active, e.g. duct, acinar, stromal, and endothelial cells, suggesting that these
cells do not represent a useful source for the generation of physiological competent β-cells for
diabetes treatments [93].

1.3. Directed differentiation of hESCs towards pancreatic β cells
1.3.1. Pancreas and β-cell development
In embryogenesis, three germ layers are formed during gastrulation: ectoderm, mesoderm,
and endoderm. A thin cup-shaped sheet of definitive endoderm (DE) is formed between
embryonic day E5 and E6 in mice. DE develops into the primitive gut tube that can be divided
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into several region with distinct development potential and gives rise to different endodermal
organs such as liver, lung, thymus, stomach, pancreas [94]. The first specification of pancreas
occurs around embryonic day 8.5 (E8.5) in mice and 3 weeks in human, with the independent
budding of the dorsal and ventral buds in the posterior region of foregut [95]. The formation of
pancreatic bud is marked by the expression of the pancreatic and duodenal homeobox 1 (Pdx1).
Lineage tracing studies demonstrated that Pdx1 is expressed from E8.5 until adults and Pdx1+
multipotent progenitors give rise to all pancreatic cells [96]. Soon later, these two buds grow into
the surrounding mesenchymal, branch in a tree-like structure and eventually fuse after rotation of
the gut to form definitive pancreatic endoderm around E12.5 [95]. The formation of endocrine
progenitors is marked by the expression of transcriptional factor neurogenin 3 (Ngn3). Genetic
lineage tracing studies showed that Ngn3+ cell exclusively give rise to pancreatic endocrine cells
[66]. Loss of functional phenotype of Ngn3+ cells leads to the specific and complete loss of all
pancreatic endocrine cells, while exocrine and duct compartment remain unaffected. The
expression level of Ngn3+ reaches maximum around E15.5 and declines towards birth.
Subsequently, the predifferentiated epithelium grows significantly in size and with distinct
endocrine and exocrine differentiation. Endocrine cells migrate into mesenchymal and aggregate
into islets of Langerhans. Although in the endocrine compartment, glucagon-expressing cells,
and dual glucagon- and insulin-expression cells appear as early as E9.5, these cells do not
contribute to mature islets of adult animals. The fully differentiated β-cells and other true
hormone-secreting cells become evident around E13.5. At E14.5, dramatic changes in pancreatic
development, termed as secondary transition, lead to the generation of numerous endocrine and
exocrine cells. During the final stages of islet formation and maturation, vascularization and
nerve innervations are frequently observed [97].
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Pancreas contains two types of functional compartment: endocrine and exocrine.
Exocrine compartment occupies more than 90% of the pancreatic mass. Residing in the exocrine
compartment, there are acinar cells that secret digestive enzymes such as lipases, carbohydrates,
and amylases, as well as ductal cells that transport these enzymes into the duodenum [98].
Although hormone-secreting endocrine cells make up only 1-2% of the pancreatic cell
population, they play an essential role in regulating glucose concentration in the body. Endocrine
compartment harbors five different endocrine cell types residing in islets of Langerhans: insulinproducing, glucagon (GCG)-secreting α cells, somatostatin (SST)-secreting δ cells, pancreatic
polypeptide (PP)-secreting PP cells, and a newly found ghrelin (GHRL)-secreting ε cells. β cells
are the most abundant cell population in the islet. In rodents, β cells make up 60-80% of the islet
and are located in the center of islets, surrounded by other endocrine cells [99]. Human
endocrine islets are composed of 40-60% β-cells and 30% α-cells. The β-cells are mixed with
other endocrine cells and are distributed evenly throughout the islet structure.
Many of the studies took years to work on embryonic development in order to deepen our
understanding for directed differentiation of ES cells into therapeutic β cells. Despite significant
progress achieved in understanding pancreatic development, many aspects of pancreatic
organogenesis are still a mystery. Therefore, studies addressing progressive lineage commitment
mechanisms and cell fate in organogenesis are of great value and significance for understanding
cell fate in pancreas development and directed differentiation.

1.3.2. ESC-derived insulin-producing β cells
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After the isolation of mammalian ESCs and the establishment of in vitro culture
conditions for maintaining their pluripotency, numerous approaches have been developed to
generate insulin-producing β cells from ESCs. The first report of the in vitro generation of β-like
cells was based on the selection of nestin-positive progenitor cells derived from mouse ESCs in
2001 [100]. This approach was proposed based on the idea that adult pancreas and central
nervous system (CNS) have similar developmental mechanisms and induced production of
neural cells from ES cells could be adapted for endocrine pancreatic cells. However, cells
generated by using this protocol showed low insulin production and poor insulin secretary
response. Also, later studies showed that nestin-positive progenitor cells give rise to insulinproducing cells as a result of uptake of exogenous insulin [101, 102].
In 2001, Assady et al. first reported that insulin-producing β cells can be generated from
hESCs by spontaneous differentiation [103]. It was the first proof-of-principle study showing
that hESCs was a potential candidate for generating β cells in vitro for cell therapy, even though
the number of insulin-positive cells was low. As of today, many groups have claimed the
generation of β cells from hESCs in vitro with modulated progress. The real breakthrough of
hESCs differentiation into β cells was transformed by D'Amour and colleagues in 2006 [104],
who first developed the stepwise approach by mimicking pancreatic organogenesis using signals
that regulate embryonic endoderm and pancreas formation.
The first and most crucial step in differentiating hESCs towards pancreatic lineage is the
specification of DE. Efficient DE differentiation is a prerequisite for generating therapeutic
insulin-producing β cells. Studies have shown that both TGF-β and Wnt signals are critical for
DE formation during gastrulation. Activin A, a TGF- β family member, has been used together
with Wnt3a to effectively induce DE specification [104-106]. Recent studies showed that the
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removal of a serum during the initial differentiation step was critical because serum components
contain activators of the phosphatidylinositol 3-kinase (PI3K) pathway that antagonizes the
ability of hESCs to differentiate in response to Activin A and Nodal [107]. Further studies
revealed that the inhibition of PI3K signaling using inhibitors such as LY294002 and
wortmannin can efficiently promote the differentiation of hESCs into DE [108, 109].
Approximately 70%~80% hESCs can be differentiated into DE cells under the treatment with
PI3K pathway inhibitors, which is higher than that achieved by activin A or Nodal treatment
alone [107]. The efficiency of DE formation can be confirmed by quantitative PCR and
immunohistochemical staining patterns of endodermal markers including SOX17, Foxa2, and
CXCR4. Expression of mesendoderm markers like Brachyury, spikes rapidly upon activin
treatment and then quickly decreases when cells assume endodermal properties.

1.4. Extracellular matrix (ECM) and stem cell

1.4.1. The role of ECM in stem cell niches
Stem cells reside in a dynamic, specific microenvironment termed as ‘niche’, which
provides extrinsic signals to control stem cell behaviors, in particular the balance between selfrenewal and differentiation. It helps sustain a stem cell pool within each tissue/organ. Since the
concept of niche was first proposed by Scholfield in 1978 in reference to mammalian
hematology [110], the content of the niche has increased in complexity. Generally, niches are
composed of stem cells and supportive stromal cells, together with the ECM in which they are
located. Also, some other factors, such as growth factors, cytokines, oxygen tension, as well as
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physiochemical factors including pH, ionic strength, shear stress and metabolites, within niches
are contributed to the regulation of stem cell behaviors [111]. However, the niche factors are
highly specialized for each type of stem cells, mainly depending on the defined anatomical
localization and function of the tissue[112]. A line of studies suggests that niches are critical for
maintaining stem cell function and the deregulation of the stem cell niche is involved in a
number of diseases associated with tissue degeneration, aging and tumorigenesis [113]. Thus, the
ability to replicate in vivo stem cell niches in vitro is likely a critical requirement for developing
fully functional cell types from stem cells.
ECM, a three-dimensional network of fibrous proteins and polysaccarides, has been
recognized as an important component in niches. It plays many essential roles in regulating stem
cell fate. The primary components of ECM are fibrous structural proteins, such as collagen,
fibronectin and laminin, and proteoglycans such as glycosaminoglycans, heparan sulfate,
chondroitin sulfate and non-proteoglycan polysaccharide like hyaluronic acid [114]. In living
tissues, cells synthesize these macromolecules and deposit them into the existing matrix via
exocytosis. However, the composition and assembly pattern of the ECM vary widely among
tissues. The intrinsic properties of ECM, such as matrix composition, structure, and elasticity, are
extremely spatially- and temporally-controlled, suggesting that they play a morphogenetic role in
guiding stem cell differentiation. Studies on the dynamics of the ECM have shown that the
interplay between cells and ECM is reciprocal [115]. As a scaffold, ECM provides anchor sites
for cells to attach and a structural support for tissues. Cells are not only able to sense and respond
to their outside environment, but also to change their environment's chemical and mechanical
properties through various signal transduction pathways. These interactions further deliver
signals to residing stem cells for guiding cell growth, differentiation, migration, survival and
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reorganization of the resident tissue [116]. Evidences have shown that laminin is the first ECM
protein produced in the eight-cell stage of embryos and involved in cell adhesion and migration
during gastrulation, whereas fibronectin, collagen, and heparan sulfate glycosaminoglycans are
produced later and assist further in germ layer differentiation and ultimate organogenesis [117,
118]. Numbers of studies have shown that the mutation or depletion of ECM genes such as
collagen, fibronectin, laminin, etc. can either impair tissue remodeling during embryonic
development or result in post-natal lethal phenotypes [119-121]. Therefore, the recognition of the
importance of ECM encourags the creation of 3D systems for growing and differentiating stem
cells.

1.4.2. ECM-stem cell interaction
Stem cells interact with ECM directly via cell membrane receptors, known as integrin.
Integrins are heterodimeric transmembrane receptors composed of α and β subunits, with
extracellular domains that bind to ECM, and cytoplasmic domains that are associated with actin
cytoskeleton and affiliated cytoplasmic proteins, such as talin, vinculin, paxillin, and α-actinin
[122]. Not only being as an integrated hook that couple the inside of a cell to ECM, integrins
also transduce external signals to the cytoskeleton and recruit a number of intracellular proteins
to ECM ligand-integrin binding sites, such as focal adhesion kinase (FAK), mitogen-activated
protein kinases (MAPKs). The activation of these signal-transduction pathways ultimately leads
to specialized patterns of gene expression and enforces a cellular decision on biological functions
such as adhesion, migration, proliferation, differentiation and survival [123, 124].
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At least eighteen α and eight β subunits have been characterized in mammals and
different types of integrins are involved in their ligand-binding specificities. ECM protein
Collagen I regulates the self-renewal of mouse embryonic stem cells through α2β1 integrin [125].
The α6β1 integrin, a laminin receptor, is required for the adhesion of neural stem cells (NSCs) to
their vascular niche [126]. Moreover, α6 integrin is identified as the only common element of a
variety of "stemness" signatures on ES cells, embryonic NSCs, and hematopoietic stem cells
[127]. An increasing body of data suggests that β1 integrin maintains stem cell niche, preserving
a stable stem cell population by controlling the balance between symmetric and asymmetric
division, and strictly regulating stem cell self-renewal and differentiation by modulating Notch
activity [125, 128-130]. Therefore, it is possible to engineer integrin-dependent cellular
interactions with ECM to control stem cell fate.

1.4.3. ECM and growth factors presentation
Beside the ability to interact directly with stem cells, recent studies discovered that ECM
also modulates stem cell behaviors by binding and establishing stable gradients of growth factors.
ECM proteins like fibronectin, vitronectin, collangens and proteoglycans (PGs) themselves, or in
combination with heparin and heparin sulphate, bind avidly to many growth factors, such as
fibroblast growth factors (FGFs), hepatocyte growth factor (HGF), vascular endothelial growth
factors (VEGFs), BMPs and TGF-beta through conserved structure modules [131]. Moreover, in
some cases, the interaction between growth factors and ECM is required for the binding of
growth factors to their receptors on the surface of cells. The interaction of FGF and heparan
sulfate chain is necessary for its binding to the receptor (FGFR) [132], and transforming growth
factor-β (TGF-β) first bind to intergral-membrane PGs during signaling [133]. Alternatively, the
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intrinsic domains within ECM proteins may act as ligands for canonical growth factor receptors
[116]. For example, EGF-like domain from laminin [134] or tenascin [135] can bind to EGF
receptors (EGFR) as solid-phase ligands and trigger signal as those induced by soluble ligands.
ECM proteins degradation by proteolytic enzymes metalloproteinases can induce local release of
intrinsic growth factor-like fragments of ECM proteins or matrix-bound growth factors from
their insoluble anchorage. Thus, ECM acts as a sink or reservoir of growth factors (bound or
intrinsic), which can be released to modulate the biological activities of stem cells.
Interaction between growth factors and ECM matrix can influence the biological
activities of growth factors. The binding of growth factors to ECM proteins protects them from
proteolytic degradation and increases their stability. Studies showed that heparin potentiates the
activity of growth factor FGF by prolonging its biological half-life from 7 to 39 hours [136].
Also, the interaction with ECM affects the diffusion of growth factors. Basic FGF diffuses
further in the presence of heparin because bFGF-glycosaminoglycan complex partitions into a
soluble phase rather than binding to insoluble glycosaminoglycans in ECM [137]. It is suggested
that the complex of bFGF and glycosaminoglycan may represent one of the active forms of
bFGF in vivo. Also, ECM functions as a physiological buffer that can trap growth factors at a
high concentration and release it slowly for binding to its receptor [138]. This may explain why
growth factors released over a short period of time can stimulate a long-term process like
angiogenesis. In turn, the interaction of growth factors and ECM may provide signals to stem
cells to modulate the expression of ECM molecules or cell surface receptors [139, 140]. It has
been proven that TFG-β stimulates the expression of major ECM proteins such as fibronectin and
collagen and their incorporation into the matrix [141]. Also, growth factors exert a selective
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effect on ECM deposition by regulating the expression of matrix degrading enzymes such as
collagenase and metalloproteinase inhibitors [140].

1.4.4. ECM biomechanical properties and stem cell fate determination
In the stem cell niche, not only biochemical properties of ECM compositions regulate a
balance between self-renewal and differentiation of cells, but physical and mechanical forces in
the local stem cell microenvironment, including the elasticity or stiffness of the ECM and the
compression forces exerted by neighboring cells, also contribute to the signaling pathways that
are critical for cell development and differentiation. The mechanical properties of ECM are
determined by a network of collagen, fibronectin, etc. [142]. The stiffness of a substrate leads to
an increasing level of intracellular tension by the contraction of cytoskeletal proteins and triggers
"pulling" forces against the matrix. Reciprocally, the forces generated inside of a cell transmit
through adhesion proteins to their surrounding structures, and induces the adaption of their
mechanical properties to the microenvironment. The interplay between cells and their
microenvironment generates an isometric tension within the cytoskeleton. Together with signals
from growth factors and morphogens, mechanotransduction pathways that involve Ras/MAPK,
PI3K/Akt, Rho/ROCK, Wnt/β-catenin etc. finely tune the gene expression that allows the
maintenance of cell shape and the regulation of cell behaviors [142-144].
It has been discovered that matrix elasticity (or stiffness) can direct stem cell lineage
specification. The mechanical deregulation in ECM is also found to be associated with aging,
disease, and injury. Diseased tissues often overexpress ECM components, making the tissue
more rigid and inhibit the cells' contractility and differentiation. For instance, the grafting of
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MSCs after myocardial infarction fails in regenerating contracting cardiomyocytes due to scarlike rigidity in the muscle [145], and instead it induces the trans-differentiation of these cells into
bone-like structure in the infarcted myocardium [146]. The elasticity of cell niches varies among
tissues, from brain tissues (0.1 kPa) to bone tissues (>30 kPa). Such natural variations in
mechanics also occur during embryonic development, e.g. EESC < EEndoderm < EEctoderm. Thus, the
temporal and spatial changes in ECM may guide hESCs as they mature and assemble into tissues.
However, most studies on cell biology have been performed on a plastic dish or glass, whose
elastic modulus is several orders of magnitude higher than nature tissues, which is one of the
possible reasons leading to de-differentiation or loss of function in these cells in some cases.
Thus, the development of in vitro technologies to mimic tissue elasticity would help stem cells
mature and assemble into functional tissues. A body of studies has demonstrated that stem cell
commitment changes in correspond to a 3D microenvironment. When human mesenchymal stem
cells are cultured on ECM characterized by stiffness values that mimic the elastic moduli of
brain, muscle or bone, they undergo tissue-specific cell fate into neurons, myoblasts and
osteoblasts, respectively [147]. Also, the increasing of substrate stiffness from 0.041 MPa to 2.7
MPa has found to be able to promote mesendodermal gene expression and terminal osteogenic
differentiation in ESCs [148]. Moreover, the inhibition of myosin II blocks all elasticity-directed
lineage specification, implying the physical effects of the microenvironment on stem cell
differentiation [147, 149]. Therefore, the mechanical environment should be taken into
consideration when engineering scaffolds or producing therapeutic cells in vitro.

1.4.5. Engineering three-dimensional (3D) scaffolds for stem cell differentiation

22

Most of stem cell studies have been performed using two-dimensional (2D) cultures.
Even though conventional 2D cultures have provided the benefit of ease, convenience, a high
cell viability, and also a simplified approach for understanding basic cellular behaviors.
Nevertheless, recent knowledge on 3D microenvironments has revealed a lot of drawbacks of
this approach. 2D culture is limited in its ability to present spatial and temporal cues to cells.
Furthermore, the metabolism and gene expression patterns of cells are frequently altered during
growth in 2D culture [150, 151]. Thus, 2D culture is not sufficient to reveal the real situation in
the body.
The recognition of the importance of dimensionality of cellular environment has
encouraged the creation of 3D cell culture matrices, also known as scaffolds. These scaffolds are
porous substrates that mimic a 3D niche, providing an ideal platform for cell-cell and cell-matrix
communications, and serving as biointeractive stages to support cell growth, migration,
differentiation and organization. The feasibility of a 3D culture for hESCs differentiating into
neural [152], cartilage [153], bone [154], vascular [155] and liver [156] tissue have been reported.
Notably, ESCs in 3D cultures have been found to display higher degree of functionality and
ability of differentiation than those cultured in a 2D culture system [157]. Moreover, hESCs that
are differentiated in 3D matrices tend to form 3D structures similar to in vivo architecture. For
examples, hESCs differentiated in a 3D scaffold have shown to form 3D intestinal 'organoids'
consisting of a polarized, columnar epithelium that is patterned into villus-like structures and
crypt-like proliferative zones expressing intestinal stem cell markers, whereas 2D culture did not
[158].
A wide range of biomaterials has been developed to for their use in 3D studies. Based on
its properties, each biomaterial is classified as either natural or synthetic. Synthetic biomaterials
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include polymers, ceramics, and metals. These synthetic materials offer the versatility of creating
3D microenvironments with tunable features, such as controllable mechanical properties,
degradation rates, porosities, and defined chemical compositions. Biodegradable poly (lactic-coglycolic acid) (PLGA)/poly (L-lactic acid) (PLA) polymer scaffolds have shown promoting for
hESC proliferation and differentiation into 3D structures such as neurons, cartilage, or liver
[159]. Many of these synthetic biomaterials, however, have poor adhesion properties due to lack
of sites for stem cell attach and proliferate. Moreover, these materials can trigger an immune
response. The biocompatibility of these materials is another concern for their suitability for
transplantation in vivo [160]. The biological or chemical modification of these synthetic
materials is thus necessary but remains challenge.
On the other hand, natural materials are attractive and have been frequently used for
developing various scaffolds for stem cell studies. They consist of components either found in
ECM, such as collagen, fibrinogen, hyaluronic acid, glcosaminoglycans (GAGs) or some other
polysaccharides derived from plants, insects or animal components, such as cellulose, chitosan,
dextran and alginate. Naturally derived biopolymers offer many advantageous properties that are
favorable for stem cell studies. First, these materials are usually biocompatible and have cellular
binding domains for cell adhesion and phenotype regulation. Second, they are intrinsically
bioactive and can regulate stem cell behaviors orchestrated with soluble signaling factors. For
example, adhesion to vitronectin and collagen I has shown to promote osteogenic differentiation
[161]. In addition, in recent years, many of these natural materials, e.g. chitosan, hyaluronic acid,
silk, Matrigel™ have been well characterized and become commercially available, with
reproducible and controlled properties. Among ECM, collagen is the most abundant protein in
mammals, comprising 25% - 33% of the whole-body protein mass [162]. So far, twenty-eight
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types of collagens have been identified, specifically, type I collagen is the most frequently used
to form hydrogels for 3D studies. 3D collagen scaffolds have been used to culture a wide variety
of stem cells for forming different variety of tissues, such as bone, cartilage, heart, ligament,
nerve, and vasculature. However, the use of a collagen gel for hESCs pancreatic differentiation
has not been reported yet.
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Objectives and Hypothesis
The use of hESCs as unlimited cell sources for generating transplantable β cells has
ignited the hope for cell-based diabetes treatment. Current studies have mostly been focused on
stepwise hESC differentiation approaches that use cocktails of various soluble signaling
molecules for directing hESC pancreatic lineage differentiation. However, cells generated with
these protocols have exhibited immature pancreatic endocrine phenotypes and cannot function
normally in vivo to correct the glucose level after transplantation in diabetic animal models. A
major difference between β-cell in the pancreas and the β-cell generated in vitro lies in the
different environment they reside in. Studies on pancreas organogenesis suggest that the
development of β cells highly depend on the interaction with various physicochemical cues in
their surrounding microenvironment. Thus, a 3D culture system would be advantageous to
imitate in vivo stem cell niches favoring cell-cell and cell-matrix interaction. In this work, we
explored the feasibility of ECM-based scaffolds for enhanced pancreatic differentiation from
hESCs.
We hypothesized that the pancreatic β-cell differentiation can benefit from a collagen I
based ECM scaffold. First, we investigated whether the most critical stage in pancreatic
differentiation—DE differentiation can be enhanced using a 3D collagen scaffold. Second, we
examined the combinatorial effect of ECM proteins on DE differentiation from hESCs, in order
to produce a robust protocol for endodermal lineage differentiation. Third, we examined the
pancreatic β-cell differentiation from hESCs in collagen-based ECM scaffold. This research will
help establish a robust protocol for generating mature β cells that can secret insulin functionally
for cell-based diabetes treatment.
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CHAPTER 2
Differentiation of Human Embryonic Stem Cells into Definitive Endoderm in Type I
Collagen Gel
2.1. Abstract
The production of pancreatic insulin-producing cells from human embryonic stem cells
(hESCs) has emerged as one of the most attractive cell therapy strategies for insulin deficient
diabetes treatment. Here, we established a three dimensional (3D) model to culture and
differentiate hESCs that are embedded in type I collagen gel. Both single cell and cell cluster
seeding approaches were tested. We discovered that cell clusters were formed within 3D
collagen scaffolds no matter what seeding format was used. However, cell cluster seeding
yielded better cell proliferation. By comparing the DE marker gene expression in cells
differentiated within 3D collagen scaffolds and traditional 2D cell culture plates, we found that
3D niches significantly enhanced the DE marker gene expression. The expression of Sox17,
Foxa2, and CXCR4, three DE marker genes, in 3D cultures increased 4.5 fold, 5 fold and 4.2
fold compared to 2D differentiation. Furthermore, our experimental results suggest that DE
differentiation benefits from single cell seeding when forming 3D cell differentiation scaffolds.

2.2. Introduction
Embryonic stem cells (ESCs) can differentiate into any type of cells in the body. The
generation of insulin producing cells from hESCs emerged as the most attractive alternative for
diabetes treatment. Current knowledge revealed that the ultimate success of an in vitro approach
to program ESCs into functional insulin-producing β-cells largely depend on the ability to
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sequentially reproduce the individual steps that characterizes normal β-cell ontogenesis during
fetal pancreatic development [163]. During this process, the first and the most critical step is the
generation of definitive endoderm (DE) population, which can be further induced to adopt a
pancreatic endocrine progenitor fate and finally differentiate into β-cells [105, 163, 164].
Unfortunately, many studies overlooked this principle tenet of development and thus limited the
progress of generating physiological functioning mature cells in the end. Therefore, it is highly
desirable to develop an efficient and reproducible protocol on initial commitment of hESCs
towards definitive endoderm.
In the past decades, strategies for inducing DE cells from hESCs has been focused on the
use of cocktails of various soluble signaling molecules such as Activin A/nodal, WNT, and FGF,
which mimic the key biochemical signaling received by cells during ingress at the primitive peak
in vivo [165, 166]. Although considerable progress has been made towards DE differentiation in
vitro, a number of questions and problems remain. For example, although signaling pathways are
conserved among many species, their particular functions (repressive or inductive) may vary
significantly among other species and activity change with timing, explaining in part the
contrasting findings between hESCs and mESCs or different hESC cell lines. Also, these
methods produce heterogeneous cell population and furthermore, express pluripotent genes
which pose a significant risk of teratoma formation and hind the further application for clinical
use [167]. In addition, mature functional β-cells have yet to be convincingly produced in vitro
[104, 168]. These findings indicate that the use of signaling molecules alone is insufficient to
resemble an in vivo environment for embryonic development and there may be important factors
are neglected in current differentiation protocols.
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In nature tissues, cells interact not only with each other, but also with the threedimensional (3D) extracellular matrix (ECM). Thus, there is a growing interest in developing 3D
scaffolds to mimic the local biochemical and mechanical 3D niche and modulate the behavior of
stem cells [159, 169]. A line of studies have demonstrated that hESCs that were cultured on 3D
biodegradable scaffolds showed distinct characteristics of their cell cycle and enhanced ability to
expand and differentiate as compared to those gown on conventional two-dimensional (2D)
culture (monolayer cultures on flat plastic cell culture plates/dishes) [156, 170]. Also, it has been
reported that ESCs could be induced to differentiate into neural, epithelial, and endothelial
lineages in 3D biodegradable scaffolds and form 3D tissue structures that were not observed in
2D culture [159, 171]. 3D structure could be critical for maintaining ESCs’ native function and
recapitulate embryonic development in vitro. The use of a 3D scaffold for ESC differentiation
would help develop mature functional cells for cell therapy.
Collagens are most abundant components in the ECM and are fibrillar structural proteins.
Due to its biocompatibility and its biodegradable property, it has been widely used as a
biomaterial to construct 3D tissue models for investigating cell behavior and differentiation. It
has reported that type I collagen can enhance viability and function of many cell types, including
smooth muscle cells, neural progenitor cells and hepatocytes [172-174]. Also, collagen I has
been shown to improve the differentiation ability of ESCs towards different specific cell lineage
[156, 175]. Especially, collagen I 3D culture promotes the reorganization of pancreatic endocrine
cell monolayers into islet-like organoids as well as improves β cell survival and insulin secretion
[176, 177]. Wang et al. showed 3D collagen scaffold promote ESCs into pancreatic β-cell
lineage specification in a mouse cell model [178]. Thus, it has been widely accepted that both
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chemical and physical factors, as well as geometric or topographical features of 3D scaffold,
contribute collectively to modulate the differentiation of stem cells into specific lineage.
In this study, we hypothesized that the 3D collagen culture may benefit for hESC
proliferation and directed differentiation towards definitive endoderm, thus helpful for
establishment of a rigorous, standard protocol of fully functional insulin-producing β cells for
islet transplantation.

2.3. Materials and Methods
2.3.1. hESC culture
Undifferentiated hES cell line, H9, was acquired from Wicell Research Institute
(Madison, WI). Cells were cultured on mitotically inactivated mouse embryo fibroblasts (MEFs)
feeder layers in DMEM/F12 medium (HyClone) supplemented with 20% (v/v) Knockout serum
replacement (KOSR, Gibco), 2 mM L-glutamine (Cellgro), 0.1 mM 2-mercaptoethanol (β-ME,
A.G. Scientific), 1 mM non-essential amino acids (Invitrogen), and 4 ng/ml basic FGF (bFGF,
Peprotech). Cells were passaged at a 1:4~1:6 split ratio every 4~7 days through collagenase IV
(1 mg/ml, Sigma) treatment combined with manual dissociation. Before use, cells were
transitioned from feeder-dependent culture to feeder-free culture to eliminate MEF feeder cells.
Briefly, cells were seeded on Matrigel (BD biosciences)-coated plates in mTeSR1 medium
(StemCell Technologies, Vancouver, Canada) and maintained in an undifferentiated state under
feeder-free conditions. Cultures were passaged at a ratio of 1: 3~1:5 every 3~5 days cells using 1
mg/ml dispase (StemCell Technologies, Vancouver, Canada). The cultures were incubated at
37oC in the atmosphere supplemented with 5% CO2. The cell culture media exchanged daily.
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2.3.2. 3D hESC definitive endoderm differentiation
3D scaffolds were prepared as follows: a type I rat tail collagen solution

(BD

Biosciences) was first diluted with sterile water and 10X phosphate-buffered saline (PBS,
Cellgro) to achieve a final collagen concentration of 1.67 mg/ml. The pH of the diluted collagen
solution was then adjusted to 7.4 using 1 N NaOH. The solution was subsequently chilled on ice
to prevent from gelation. At the same time hESCs were treated with AccutaseTM (Millipore) or
dispase (1 mg/ml) (StemCell technology) in order to obtain single cells or cell clusters
suspension. The enzyme treated cells were suspended in 10× DMEM medium (maintaining
physiologic osmolarity at 250~300 mOsM) and then added to the ice-chilled collagen solution to
achieve a final collagen concentration of 1.5 mg/ml and the cell density of 2.5 × 106 cells/ml.
Thereafter, 0.4 ml aliquots of the cell-collagen mixture were transferred into wells of a 24-well
tissue culture plate and incubated at 37oC, 5% CO2 for 30 min to form scaffolds. Once a scaffold
has formed, 0.5 ml of the cell culture medium was added to the top of the scaffold. The cellladen scaffolds were then placed into a CO2 incubator and allowed cells to grow for 24 hours
before initiating DE differentiation.
DE differentiation was carried out by following a protocol developed by D’Amour et al.
[104]. In brief, hESCs were washed briefly with PBS+/+ (Cellgro) before initiating the
differentiation and then cultured in RPMI 1640 medium (Gibico) supplemented with
recombinant growth factors 100 ng/ml Activin A (PeproTech Inc.) and 25 ng/ml Wnt3a
(PeproTech Inc.) for 1 day. After 24 hours, the medium was replaced with a fresh RPMI 1640
medium supplemented with 0.2% defined FBS and 100 ng/ml Activin A. The differentiation
continued for another 72 hours.
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2.3.3. Scanning electron microscopy (SEM)
Cell-collagen scaffolds were fixed with 2.5% (v/v) glutaraldehyde (EM Sciences, Fort
Washington, PA) at pH 7.4 for 2 h. After washing with PBS each for 10 min three times, the
scaffolds were post-fixed in 2% osmium tetroxide (EM Sciences) for 2 h and dehydrated with
25%, 50%, 75%, 85%, 95%, and 100% (v/v) of ethanol before lyophilization. The lyophilized
scaffolds were mounted on aluminum stubs with a double-stick carbon tape and sputter coated
with gold before SEM, using a Jeol Field Emission scanning electron microscope (JSM-6335F;
JEOL USA, Peabody, MA) at an accelerating voltage of 10 kV.

2.3.4. Cell viability assay within 3D collagen scaffolds
The cell viability within a collagen scaffold was determined using calcein-AM/
propidium iodide (PI) staining kit (Falcon) by following the manufacture's instruction. The kit
contains two fluorescent probes that measure cell viability. Live cells are stained with green
fluorescence due to the enzymatic conversion of the nonfluorescent, cell-permeate dye calceinAM to the intensely fluorescent calcein (excitation: 495 nm, emission: 515 nm). Dead cells are
identified by staining with PI, which enters cells with damaged membranes, and, upon binding to
nucleic acids, produces a bright red fluorescence (excitation: 495 nm, emission: 635 nm). PI is
excluded by the intact plasma membrane of live cells. Live/dead staining was prepared with 2
mM calcein AM and 4 mM PI in PBS. Form assessment of immobilized cells, 0.2 ml of the dye
solution was added to 0.4 ml scaffold samples. The samples were incubated with the dyes
(calcein AM and PI) for 10 min. The dye solution was removed and 0.5 ml of PBS was added
and incubated for another 30 min. The PBS buffer was subsequently removed in order to
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stabilize the cell containing scaffold before taking microscopy images with an Olympus upright
fluorescence microscope (IX71, Tokyo, Japan) equipped with a supersensitive CCD camera
(mode number ROLERA-XR, Surrey, BC, Canada) controlled by an imaging analysis software
Slidebook (Intelligent Imaging Innovations, Inc., Denver, CO).

2.3.5. AlamarBlue cell proliferation assay
The proliferation of hESCs and their derived cells during DE differentiation within 3D
scaffolds was determined using an oxidation–reduction indicator alamarBlue (Alamar
BioSciences, Sacramento, CA) agent that reacts to viable cells, generating fluorescence to
detection. To evaluate cell proliferation within the collagen scaffolds during DE differentiation,
we inoculated the scaffolds with 2.5×106 cells/ml hESCs. hESCs were differentiated into DE
cells, as described above. At specified time intervals, 400 µl of differentiated medium containing
10% alamarBlue was added to each well after washing the scaffolds once with PBS buffer and
the plate was incubated at 37°C for 4 hrs. The fluorescence of the cell culture broth was
measured by fluorescence spectrophotometer using a fluorescence excitation wavelength of 540–
570 nm (peak excitation is 570 nm). Read fluorescence emission at 580–610 nm (peak emission
is 585 nm). All measurements were performed at room temperature. Finally, results were
analyzed by plotting fluorescence intensity versus a duration time.

2.3.6. RNA extraction and quantitative RT-PCR (qRT-PCR)
Total RNA was extracted from cultured cells using the RNeasy Plus Mini kit (Qiagen,
Valencia, CA). RNA samples were digested with DNase I (1 unit per µg RNA, Promega
Corporation, Madison, WI) prior to reverse transcription (RT) to remove any contaminated
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genomic DNAs. A portion of 1 µg of RNA was used to prepare cDNA. The reverse transcription
was performed using ProtoScript® First Strand cDNA Synthesis Kit (New England Biolabs).
Quantitative PCR was carried out using Realplex Real-Time PCR machine (Eppendorf). The
PCR reaction solution consisted of 10 µl of SYBR Green PCR master mix (Roche), 0.15 µl of 10
mM forward and reverse primers that are specific to the target marker genes, 7.7 µl of nucleasefree water, and 2 µl of diluted template cDNA in a total volume of 20 µl. Initial enzyme
activation was performed at 95°C for 15 min, followed by 40 cycles of denaturation at 95°C for
15 s, and primer annealing/ extension at 60°C for 1 min. Melting curve analysis was performed
at 95°C for 1 min, 60°C for 30 s and 95°C for 30 s. The relative expression level of each gene
was normalized against a house-keeping gene, β-actin. RNA samples collected from
undifferentiated hESCs served as control. Primer sequences were summarized in Table 1. Each
experiment was carried out in triplicate.

2.3.7. Statistical analysis
All experiments were carried out at least in triplicate. Unless otherwise indicated in the
text, all analytical measurements were repeated three times. All data were expressed as means ±
standard deviations. Statistical analysis was performed with Student’s t-test, with p<0.05
considered as statistically significant.

2.4. Results
2.4.1. hESC maintenance on two culture system
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As shown in Figure 1, undifferentiated hESCs grown on MEF feeder layer (A-C) and
Matrigel (D-F) showed as compact, multicellular colonies. Also, they exhibited a high nuclearto-cytoplasm ratio and prominent nucleoli, which is a characteristic feature of hESCs. After 5
passages of culture, the expressed of SOX2, SSEA4, and TRA-1-60 were stained positively
(Figure 1. G-I), indicating the pluripotency of the hESCs.

2.4.2. Collagen I scaffold characterization
Unseeded and hESC seeded collagen I scaffolds were characterized morphologically by
SEM micrographs (Figure 2). The microscopic structure of a collagen scaffold showed a
homogeneous fibrillar and porous 3-D network, indicating spacious areas for cell growth and
differentiation. The diameter of the collagen nanofibers was 230 nm on average and pore size
was about 0.65 µm3 estimated using NIH Image J software. SEM micrographs of seeded
scaffolds showed that the hESCs were tightly attached to the scaffolds and secreted ECM-like
proteins (Figure 2B), suggesting the suitability of the collagen type I scaffold for hESC growth.

2.4.3. Morphological and viability analysis of DE differentiated hESCs within collagen
scaffolds
The study aimed to compare the viability and proliferation between two different cell
seeding methods, i.e. single cell vs. cell cluster seeding. Cell morphology and viability were
monitored. It was found that cells remained single on day 2 of seeding within collagen scaffolds
when the single cell seeding approach was applied (Figure 3A). The formation of cell clusters
was observed with the progression of differentiation (Figure 3B). In contrast, cells started
forming aggregates on day 2 when the cell cluster seeding approach was used (Figure 3C), and
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the size of cell clusters increased significantly on day 4 post differentiation (Figure 3D). The cell
viability within 3D collagen scaffolds was approximately 98% during the time period of
differentiation (Figure 3E-3H). These results suggest that both single and cluster hESCs can
survive and proliferate within the 3D collagen scaffolds.

2.4.4. Proliferation rate of DE differentiated hESCs within collagen scaffolds
To examine cell growth during differentiation, the cell-laden scaffolds were incubated
with the AlamarBlue substrates for 4 h and the fluorescence of solution was measured, which
indicated the cell proliferation rate. As revealed in Figure 4, cell proliferation rate was 3-fold
higher within a collagen scaffold when the cluster seeding approach was used as compared to
single cell seeding approach.

2.4.5. hESC DE differentiation in 2D and 3D
We then investigated the directed differentiation of hESCs to DE within collagen
scaffolds. For inducement of the DE differentiation, hESCs were seeded into collagen scaffolds
as either single cells or cell clusters, and grown in a DE differentiation medium for 4 days. The
expression of DE markers: Sox17, Foxa2 and CXCR4 in the induced cells on day 2 and day 4
were detected to ascertain whether the hESCs were differentiated into DE concomitantly with
their proliferation within collagen scaffolds. Undifferentiated hESCs served as a control for the
assay. As shown in Figure 5, analysis of gene expression showed that the treated samples, which
were differentiated for 4 days under treatment of 100 ng/ml activin A and 25 ng/ml Wnt3a,
expressed DE markers SOX17, FOXA2, CXCR4 in both 2D and 3D culture, which confirmed the
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generation of definitive endoderm from hESCs. Especially, 3D culture by using both cell
seeding methods significantly increased the expression level of DE markers as compared to 2D
culture, however, the single cell seeding approach resulted in higher expression level of DE
markers (SOX17>250-fold, FOXA2 >500-fold, and CXCR4 >1000-fold on day4 as compared to
undifferentiated hESCs) than cell cluster seeding approach (SOX17>100-fold, FOXA2 >300-fold,
and CXCR4 >500-fold on day4 as compared to undifferentiated hESCs). Meanwhile, significant
decreases of OCT4 on day4 after induced differentiation in both 2D and 3D cultures indicated
the loss of pluripotency of hESCs. In addition, the cells in 3D scaffold showed a decreased level
of ectoderm marker PAX6 and mesoderm marker Brachyury, indicating the DE differentiation
was dominant in the cultures.

2.5. Discussion
DE differentiation is critical for hESC pancreatic lineage differentiation. In our previous
study, we demonstrated that more mature insulin-producing β cells could be generated from
mouse ESCs (mESCs) when differentiating them within a collagen scaffold [179]. In this work,
we investigated the feasibility of differentiating hESCs into matured β cells. As the DE
differentiation is critical to the hESC pancreatic lineage specification, we investigated its
differentiation within a 3D collagen scaffold. We found that the cell proliferation rate and DE
differentiation efficiency are significantly affected by the seeding approach. The experimental
results suggested that cells proliferated much faster when they were seeded in clusters, as
compared to those seeded in single cell suspension. Also, DE differentiation was greatly
enhanced in 3D culture, especially when single cell approach was applied. To the best of our
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knowledge, this study was the first to explore the feasibility of differentiating hESCs into
endoderm lineage in 3D collagen scaffold.
3D culture provides a means to study hESCs growth and differentiation in a
physiologically relevant manner in vitro. The ideal scaffold for tissue engineering would have a
structural component to provide mechanical support and a network structure consisting of large
pores to allow cell expansion and the diffusional transport of nutrient and waste molecules [179].
Collagen scaffold is an ideal candidate for hESCs encapsulation and differentiation because it
has relatively large pores (Figure 2A), support cell attachment, its gel formation is simple [180].
From SEM images (Figure 2B), collagen has shown to support cells attachment via cellextracellular matrix interaction. Also, hESCs grown in 3D environment showed formation of 3D
aggregates structure, as revealed in bright field images, which was not observed in conventional
2D culture. We think the pore size, fibrillar density and organization of the collagen fibers favor
cell migration and promote the formation of aggregates structures in the process of hESCs
differentiation.
It is crucial to maintain hESC viability while perform differentiation process. Therefore,
we cultured hESCs in growth medium for 24 hours and initiated hESC DE differentiation using
Activin A and Wnt3a on day one of seeding, which will prevent apoptosis of hESCs after cell
dissociation. As shown here, collagen scaffold was capable of maintaining hESCs viability in the
process of differentiation by using both cell seeding methods.
To determine whether DE can also be efficiently derived from hESCs in 3D collagen gel,
single cell and cell cluster preparations of hESCs were induced to differentiate in 2D or 3D
cultures following a well-established differentiation protocol. It is important that hESCs seeded
within the scaffolds maintain their pluripotency prior to differentiation. The pluripotency related
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gene Oct4 was decreased by the process of definitive endoderm differentiation accompanied by a
transient expression of mesendoderm marker, Brachyury, 24 hours after activin A and Wnt3A
treatment (day 2 after inoculation), which indicated the hESCs proceeded through the mesoderm
to endoderm transition. Moreover, the embedded cells in collagen gel expressed much higher
definitive endoderm marker genes level compared to 2D culture when they reached their peak on
day 4 after differentiation, with SOX17 increase around 4.5 fold, FOXA2 around 5 fold and
CXCR4 around 4.2 fold as compared to 2D culture. Interestingly, the expression of DE gene of
differentiated cells seeded as clusters did not increased as significantly as those cultured as single
hESCs. The enhanced efficiency of hESC differentiation into DE by single cells seeding could
be explained by proper infiltration of single cells into the pores of the scaffolds, which would
provide relatively uninhibited access of media and growth factors to the cells. Also, we observed
some outgrowth of cells when hESCs were seeded as cell clusters in collagen gel, which
probably inhibit the grow factor diffusion and slow down the differentiation process. However,
the proliferation rate in 3D culture by using single cells seeding was lower than cell clusters
seeding. The possible reasons could be differentiation could be easily started from single cells
which slow down their proliferation.
In summary, we have established a 3D culture model to differentiate hESCs into
definitive endoderm, which is most critical stage for pancreatic differentiation. The seeded
hESCs proliferated and maintained high viability in the collagen culture. Upon directed
differentiation, the seeded hESCs can be differentiated into DE with a higher efficiency when
cells were seeded as single cells. This system may provide an alternative strategy for generating
insulin-producing cells for cell-based diabetes treatment
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Chapter 3
Combinatorial Effect of ECM Proteins on 3D Human Embryonic Stem Cells Definitive
Endoderm Differentiation

3.1. Abstract
hESCs are potential renewable cells sources for cell-based therapies. Here, we reported a
novel three-dimensional (3D) model to derive DE cells from hESCs by using collagen I and
various ECM proteins such as fibronectin (FN), laminin (LN) and vitronectin (VN). It is found
that, single ESCs formed clusters and remained a high viability (>95%) within collagen scaffolds.
More importantly, demonstrated by qRT-PCR, immunohistochmical staining, flow cytometry
results, mixture of ECM proteins by incorporating of FN, LN and VN together in 3D collagen
matrices produced more than 90% of SOX17+ DE cells with DE markers genes Sox17, Foxa2
and CXCR4 increased by 79-fold, Foxa2 60-fold and CXCR4 75-fold respectively Also, the cells
in collagen-ECM scaffold secreted more ECM proteins such as fibronectin 1, laminin gamma 1,
collagen type IV alpha 1, collagen type III alpha 1, collagen type I alpha 2 as showed by qRTPCR. Immunohistochemical staining showed that more collagen IV produced in collagen
scaffold with addition of ECM protein mixture. The method described here presents a significant
step towards the efficient generation of DE cells for use in regenerative medicine and drug
discovery, as well as a platform for studying cell fate specification during development.

3.2. Introduction
It has proven to be a challenge that ES cells are directed to differentiate into pure
endodermal populations in vitro [181, 182], likely because the organ development requires a
strict temporal and spatial control at each stage. It is well known that extracellular matrix (ECM)
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is a key component in stem cell niches and plays an important role in cell adhesion, migration,
proliferation, and differentiation [183]. ECM not only provides a support for cells and tissues,
but can also bind to growth factors, cytokines, and other soluble signaling molecules and
transduce them to cytoskeleton to trigger signaling transduction pathways and ultimately affect
gene expression, thereby changing the fate of cells [123, 184, 185]. Consequently, it is critical to
mimic this in vivo environment when designing an in vitro hESC differentiation system.
In this chapter, we showed that DE differentiation can benefit from the use of collagen
scaffolds which offer 3D environments that allows cell-cell and cell-ECM interaction. While
collagen is a good biomaterial for fabricating a hydrogel scaffolds, it is interested in determining
whether the DE differentiation can be further improved if other ECM proteins are mingled with
collagen when fabricating scaffolds. It has been known that non-collagenous ECM proteins such
as laminin (LAM), fibronectin (FN), and vitronectin (VN) also play important roles in cell
adhesion, migration, proliferation, and differentiation. FN is widely expressed by multiple cell
types and is critically important during embryogenesis [186]. George et al.’s work demonstrated
that the disruption of FN gene in ESC resulted in defects in mesoderm, neural and vascular
development [187]. In addition, it has shown that FN was acquired when ESCs differentiated
into endoderm [188] as well as many endoderm-derived tissues such as lung and pancreas [189,
190]. LM, a family of glycoproteins, is the major constituent of basement membranes between
primitive ectoderm and endoderm. By interacting with cells mediated by integrins, dystroglycan,
and other cell surface receptors, LM contributes to cell survival, phenotype maintenance, and
differentiation [191]. Specifically, LM is upregulated during endoderm epecification [192]. Also,
Lin et al. demonstrated that the differentiation of insulin-producing cells (IPCs) from human
mesenchymal stem cells could be enhanced when LM and FN are used [193]. Another study also
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revealed that collagen 3D scaffolds prepared in combination with adhesive ECM proteins, such
as FN and LM, offer better cues for mesenchymal stem cell neuron differentiation, even without
the use of chemical differentiation factors [194], suggesting that ECM proteins can provide
signals for directing cell differentiation. Vitronectin (VN) is another widely distributed high
molecular weight glycoprotein found in most sites of ECMs and is known to promote cell
adhesion, migration, differentiation, and cytoskeletal organization. It affects cell morphology as
well. VN has been identified in fetal islet tissue emerging from pancreatic ducts during
development, suggesting its role in DE specification [195]. It has been proved that the addition
of VN in gel condition significantly improves β-cell survival and insulin secretion [177]. Even
though a lot of studies have been carried out to investigate the influence of ECM proteins on cell
behavior and differentiation, there have been few reports on endoderm-derived cell
differentiation.
Here, we choose collage type I as a major component of the scaffold combined with
various ECM proteins such as LAM, FN, and VN to investigate the combinatorial effect of these
components on DE differentiation within collagen scaffolds.

3.3. Materials and methods
3.3.1 3D hESC culture
The hESC line H9 was acquired from Wicell Research Institute. Cells were maintained
in an undifferentiated state on growth-factor-reduced Matrigel (BD Biosciences, Bedford, MA)coated cell culture plates in mTeSR1 medium (StemCell Technologies, Vancouver, Canada).
Cells were passaged every 3~5 days at a splitting ratio of 1: 4~1:6 through dispase (1 mg/ml)
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(StemCell Technologies, Vancouver, Canada) treatment combined with manual dissociation. The
cells were incubated at 37oC in the atmosphere supplemented with 5% CO2. The cell culture
media was exchanged daily.
3D scaffolds were prepared as follows: type I rat tail collagen solution (BD Biosciences,
Bedford, MA) was diluted with sterile H2O and 10× phosphated-bufferd saline (PBS) (Mediatech
Inc., Manassas, VA) to maintain the physiologic osmolality at 250~300 mOsm. The final
collagen solution concentration was 1.5 mg/ml. To produce ECM protein mixed collagen
scaffolds, collagen gel solution was added with variable amounts of FN (BD Biosciences,
Bedford, MA), LM (Trevigen, Gaithersburg, MD), or VN (Trevigen, Gaithersburg, MD) stock
solution to final concentration of 25, 25, and 4 μg/ml, respectively. The pHs of these solutions
were adjusted to 7.4±0.2 by the addition of 1 N sterile NaOH. These solutions were chilled on
ice to prevent from gelation until use.
Before seeding hESCs into scaffolds, the ROCK inhibitor, Y-27632 (Calbiochem,
California, USA) was added to the cell cultures at 10 µM for 2 hrs before the cells were
dissociated by AccutaseTM (EMD Millipore, Billerica, MA) treatment. The single cell suspension
was obtained after centrifugation at 300 x g for 5 min and suspended in mTeSR1 medium. The
live cell number was determined by trypan blue staining assay using a hematocytometer. The cell
suspension was then added to the ice-chilled collagen solution along with different ECM proteins
to achieve a final cell density of 2.5 × 106 cells/ml. Thereafter, 0.4 ml aliquots of the cellcollagen with ECM protein mixtures were transferred into wells of 24-well tissue culture plates
and incubated at 37oC, 5% CO2 for 30 min to 1 h to achieve gelation. 0.5 ml of cell culture
medium (mTeSR1 with 10 µM Y-27632) was added to the top of the scaffolds once the scaffolds
have formed. The cell-laden scaffolds were returned to the incubator and allow cells to grow
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within the scaffolds for 24 hrs before initiating differentiation. In two-dimensional (2D) cultures,
cells were plated onto Matrigel-coated tissue culture plates at the same density, followed by
same differentiation procedure as 3D cultures do.

3.3.2. hESC DE differentiation
The DE differentiation was optimized by differentiating hESCs in two different DE
medium: (1) hESCs were fed with RPMI 1640 medium (Invitrogen) supplemented with 100
ng/ml activin A (PeproTech Inc.) and 25 ng/ml Wnt3a (PeproTech Inc.) for 1 day and after 24
hours, medium was replaced with fresh RPMI 1640 medium supplemented with 0.2% defined
FBS and 100 ng/ml activin A for another 72 hours (medium A). (2) hESCs were fed with
DMEM/F12 medium supplemented with 0.2% BSA (Sigma), 0.5% B27 (Invitrogen), 0.5% N2
(Invitrogen), 100 ng/ml activin A (PeproTech Inc.) and 25 nM wortmannin (EMD Millipore) for
4 days (medium B). The DE differentiated efficiency will be compared and the medium that
resulted in higher DE efficiency would be used for DE differentiation in 3D culture experiments.

3.3.3. Cell viability
The cell viability within scaffolds was determined using live/dead cell dual staining kit
(Sigma-Aldrich, Saint Louis, MO) by following the manufacture’s instruction. The kit contains
two staining probes for the simultaneous detection of viable and dead cells. Live cells with
intracellular esterase activity can convert the nonfluorescent, highly lipophilic, cell-permeable
dye calcein-AM into the fluorescent dye calcein which emits green fluorescence (excitation: 495
nm, emission: 515 nm). Dead cells are identified by a nuclei staining dye PI which passes
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through damaged cell membranes, and upon binding to DNA double helix, producing red
fluorescence (excitation: 495 nm, emission: 635 nm). PI is excluded by the intact plasma
membrane of live cells. After washing with PBS three times, cell-laden scaffolds were incubated
with 200 µl of the live/dead staining solution at 37oC for 15 min. The excess dye solution was
removed afterwards and 0.5 ml of PBS was added on the top of the scaffold. Excess buffer was
subsequently removed in order to stabilize the cell-laden scaffolds for imaging. Samples were
examined under an Olympus upright microscope (IX71, Tokyo, Japan) equipped with a
supersensitive CCD camera (mode number ROLERA-XR, Surrey, BC, Canada) controlled by an
imaging analysis software Slidebook (Intelligent Imaging Innovations, Inc., Denver, CO).

3.3.4. Scanning electron microscopy (SEM)
3D samples were washed with Dulbecco’s phosphate buffered saline (DPBS) buffer for at
least 3 times to remove all proteins in the culture medium or other impurities. The scaffolds were
then fixed with 2.5% (v/v) glutaraldehyde (EM Sciences, Fort Washington, PA) in PBS buffer at
pH 7.4 for 2 h at room temperature. After three 10-min washes in PBS, the samples were postfixed with 1% osmium tetroxide (EM Sciences) for 1 h at room temperature. Followed by two
10-min washes, the fixed scaffolds were dehydrated in a series of graded ethanol: 30%, 50%,
70%, 90% and two times of 100% v/v for 10 min each. Then, the cell-laden scaffolds were
allowed to dry overnight on aluminum foil in fume hood. The dried scaffolds were mounted on
SEM sample stages using double-stick carbon tape and sputter coated with gold-palladium
before examination. Finally, the specimens were analyzed using a FEI/Philips XL30 FEG ESEM
(FEI, Hillsboro, OR) at an accelerating voltage of 10 kV.
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3.3.5. Total RNA extraction and quantitative RT-PCR
To detect gene expression in cells grown in 2D or 3D cultures, the total RNA was
extracted from cultured cells using a RNeasy Plus Mini kit from Qiagen. Prior to reverse
transcription (RT), RNA samples were digested with DNase I to remove contaminated genomic
DNA. 1 µg of RNA was used to synthesize cDNA. Reverse transcription was performed using a
High Capacity cDNA Reverse Transcription Kit from the Invitrogen followed by the
manufacture’s instruction. Quantitative real-time PCR (qRT-PCR) was carried out using the
Power SYBR Green PCR master mix (Applied Biosystems) and was performed on the Realplex
Real-Time PCR system (Eppendorf, Realplex4 model). Initial enzyme activation was performed
at 95°C for 15 min, followed by 40 cycles of denaturation at 95°C for 15 s, and primer
annealing/extension at 60°C for 1 min. Melting curve analysis was performed at 95°C for 1 min,
60°C for 30 s and 95°C for 30 s. The relative quantification was performed against a standard
curve and quantified values were normalized against the house-keeping gene β-actin.

3.3.6. Flow cytometry
For 3D culture, hydrogels were digested by using 2 mg/ml collagenase solution (Life
Technologies) for 30 min at 37oC. After centrifugation at 300 x g for 5 min and aspiration of
supernatant, the cells were then treated with 0.25% typsin with EDTA (sigma) to further digest
the cells into single cell suspension. Cells were filtered through 70 mm cell strainer (BD
FalconTM) to remove the clumps. For 2D culture, cells were dissociated using Accutase TM cell
detachment solution (Millipore) for 5 min followed by removal of trypsin by centrifugation.
Cells were fixed with 4% paraformaldehyde and permeabilized with ice-cold methanol. Cells

46

were labeled with PE mouse anti-human Sox17 (BD Biosciences) at 5 µl per 1 × 106 cells for 45
min at room temperature in the dark. Cells labeled with PE mouse IgG1ĸ was used as an isotype
control. Cells were washed three times and resuspended in PBS with 10% inactivated FBS and
0.09% sodium azide. Samples were acquired on a Becton-Dickinson fluorescence activated cell
sorter (FACS) Calibur 4-color flow cytometer and data analyzed using Bection-Dickinson
CellQuest software. Data were gated using forward and side scatter to eliminate debris and the
resulting histograms plotted to reflect the mean fluorescence intensity of Sox17 versus IgG1ĸ
isotype control.

3.3.7. Immunohistochemical and immunocytochemical staining
The cryosectioning of cell-laden scaffolds was performed as described elsewhere [196].
In brief, the scaffolds were fixed using 10% neutral-buffered formalin solution (NBF) for 3 hrs.
After overnight infiltration with a series of 20% sucrose and sucrose/OCT® solution, the
scaffolds were placed in a peel-away mold (VWR, south Plainfield, NJ) in tissue freezing
medium (Tissue-Tek OCT Compound, Sakura-Fintek). All the molds were then placed into the
MICROM cryostat (Richard-Allan Scientific) chamber and the samples were allowed to freeze at
-20oC for at least 30 min. Routine frozen sectioning was performed by collecting 8-µm sections
onto positively charged slides. The scaffold sections were either collected or air-dried for a
minimum of 30 min. Before staining, sections were hydrated in PBS for 10 min and then
incubated in a blocking buffer (PBS containing 5% normal goat serum, 0.3% Triton X-100) for 1
h and thereafter in primary antibodies for 12 h at 4°C diluted in the blocking buffer. The primary
antibodies used in this study were mouse monoclonal anti-human Sox17 (R&D Systems; 1:50),
rabbit monoclonal anti-Foxa2 (Abcam; 1:1000), rabbit anti-Collagen IV (Abcam; 1:200). The
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secondary antibodies used were DyLightTM 488 conjugated goat anti-mouse IgG (Thermo
Scientific; 1:500) and Rhodamine (TRITC)-conjugated donkey anti-rabbit IgG. To stain 2D
culture samples, cells seeded on Matrigel-coated plates were fixed with 4% paraformaldehyde
(Sigma). After being treated in the blocking buffer for 45 min at room temperature to inhibit
nonspecific binding, cells were labeled with primary and secondary antibodies as described
above. DAPI (Research Organics) were used to counterstain cell nucleus. Images were captured
using an inverted fluorescence microscope (Olympus, IX71, Japan).

3.3.8. Statistical analysis
All experiments were carried out at least in triplicate. All quantitative values were
presented as mean ± SD. Statistical analyses were performed using student’s t-test and p-value
≤0.05 were considered statistically significant.

3.3.Results
3.4.1. PI3K inhibitor enhanced DE differentiation from hESCs
Generating appropriate DE population is a crucial step in producing derivative lineages
and functional cell population. Most protocols use Activin A and Wnt3a described by D’Amour
[104] to generate DE cells. Recent studies found out PI3K signaling was evolved in DE
differentiation, here we tested whether the addition of wortmannin, a PI3K inhibitor, would
improve our DE protocol. The qPCR results showed that the addition of wortmannin was able to
augment the expression of DE markers SOX17 and FOXA2 by 8-fold and 13-fold, respectively,
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as compared to D’Amour’s protocol (Figure 6A). Low expression of pluriopotency marker
(OCT4), mesoderm (Brachyury) and ectoderm (PAX6) lineages marker provided evidence that
wortmannin can enhance DE differentiation. Also, the differentiation efficiency was evaluated
by flow cytometric analysis of SOX17+ cells, revealing that the percentage of SOX17+ cells was
70% when cells were treated with Activin A in combination with PI3K inhibitor as compared to
32% when cells were treated with Activin A in combination of Wnt3a. Consistent with the gene
expression and flow cytometric analysis, immunostaining revealed that larger population of cells
were stained both SOX17 and FOXA2 positive when cells treated with wortmannin in
combination with Activin A. Taken together, these finding indicated that the inhibition of PI3K
pathway does significantly promote differentiation of hESCs into endocrine lineage.

3.4.2 Proliferation and morphological changes of hESCs-differentiated DE cells within scaffolds
To reveal the potential of ECM-collagen scaffolds for directing hESC pancreatic lineage
differentiation, undifferentiated single suspended cells were seeded into collagen along with
ECM proteins (for 3D cultures) or onto Matrigel-coated cell culture plates at a cell density of 2.5
× 106 cells/ml (for 2D cultures). Cells grown in either 2D or 3D cultures both proliferated rapidly
but differed in their morphology (Figure. 7). In 2D culture, cells were predominantly flat,
stretched endoderm-like cell morphology throughout the entire differentiation period. In contrast,
cells formed clusters after 2 days of differentiation in 3D cultures (Figure. 7). The number of
cells and the size of clusters increased significantly. The spherical tissue-like structures were
formed on day 4 of DE differentiation. Interestingly, within the collagen gel matrix containing
VN, cells exhibited a highly elongated branch like junctions without forming significant clusters.
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The viability of differentiated DE cells within scaffolds was determined on day 2 and day
4 by calcein-AM/PI live/dead cells dual staining. As shown in the fluorescence images (Figure.
8), there appear to be a high percentage of live cells (green) with only fewer dead cells (red),
mostly found along the side of the cluster. The average size of the cell clusters was about 150250 µm. The live/dead staining also permitted the observation of the high percentage of live cell
clusters with outgrowth and cluster-cluster connection. These results demonstrated that the
dissociated hESCs could be immobilized in collagen along with ECM proteins with a high
viability.

3.4.3. Morpholigical analyses of DE differentiated cells in 3D collagen-ECM scaffolds
To characterize the in vitro environment of the 3D scaffolds for hESC differentiation, we
examined the structure of collagen-ECM scaffolds and the morphology of DE differentiated cells
within these scaffolds by means of SEM. The collagen-ECM scaffolds showed similar
microscopic structure of porous fibrillar network consisting of packed and long fibrils with
approximately 200-300 nm diameter (Figure. 9). However, the addition of ECM components
(LAM, FN or VN) changed the structures of the network. For example, Col I matrices alone
showed heterogeneous fibrillar network in pore size and fiber size (Figure. 9A). The addition of
LN (25 µg/ml) increased the matrix heterogeneity with some smaller fibrils twisted together to
form larger fibrils, which appear like aggregates and amorphous regions (Figure. 9C). The
mixing with FN and VN induced a much denser fiber network with smaller pore sizes (Figure.
9I). Also, SEM micrographs of seeded scaffolds showed that the cells differentiated in 3D
cultures were tightly attached to the scaffolds and secreted ECM-like proteins, suggesting the
suitability of the collagen-ECM scaffold for hESC growth and differentiation
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3.4.4. Enhancement of DE differentiation in 3D collagen-ECM scaffolds
To examine whether ECM-collagen scaffolds can improve the DE differentiation from
hESCs, gene expression profile of DE markers such as Sox17, Foxa2, and CXCR4 were analyzed
after 4 days of DE differentiation through qRT-RCR assay. As shown in Figure.10A, the
mixing of LM or FN in Col I matrices increased DE marker Sox17, Foxa2 and CXCR4
expression by 103 fold, 7 fold, 19 fold or 65 fold, 24 fold, 28 fold, respectively as compared to
those detected in 2D DE differentiation. However, the mixing of VN with collagen did not
improve the DE differentiation, which showed similar expression level as those in 2D DE
differentiation. Interestingly, the mixing of LM, FN and VN with collagen significantly
improved the DE differentiation, indicated by the increased gene expression of Sox17 79-fold,
Foxa2 60-fold and CXCR4 75-fold as compared to those in 2D hESC DE differentiation,
suggesting that FN, LM, VN may need to work synergistically to maximize the enhancement of
DE differentiation. We also found the remarkable downregulation of pluripotency markers, Oct4
and Nanog in cells differentiated within scaffolds as

compared to those detected in 2D

differentiation, indicating the 3D cultures could further decrease the pluripotency of hESCs
during DE commitment than 2D cultures. In addition, the cells differentiated within scaffolds
expressed a decreased level of ectoderm markers PAX6, Sox3 and mesoderm markers Brachyury
and N-CAD, suggesting that more cells were differentiated towards DE lineage when they were
differentiated within scaffolds. This observation was confirmed by flow cytometric analysis. As
shown in Figure. 10B, 10% more SOX17+ cells were detected in hESCs differentiated within
collagen scaffolds as compared to those differentiated in 2D cell culture plates. More than 90%
of cells in cell clusters formed within FN-LM-VN-collagen scaffolds were DE cells.
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Immunofluorescent staining showed that above 95% cells differentiated within FN-LMVN-collagen scaffolds expressed Sox17 and Foxa2 simultaneously, while only about 70% cells
were both positive in cells differentiated in 2D cultures (Figure. 11). Moreover, the DE
differentiated cells are organized into clusters inside of the scaffolds, resembling the formation
3D structures.

3.4.5. 3D matrices improve the secretion of ECMs by DE-differentiated cells
The gene expression level of ECM components produced by DE differentiated cells in
3D and 2D environments were examined through qRT-PCR assay. Figure. 12 showed that
differentiated DE cells cultured in 3D scaffolds expressed higher gene expression levels of
fibronectin 1 (FN), laminin gamma 1 (LM), collagen type IV alpha 1 (Col IV), collagen type III
alpha 1 (Col III), collagen type I alpha 2 (Col 1α2) than in 2D culture, which imply that the ECM
secreted by cells in 3D may further improve the DE differentiation of hESCs. However, Col 1α1
gene expression in 3D cultures was lower than that in 2D cultures. The mechanism underlying
the increased expression of these ECM proteins in 3D cultures needs to be further investigated.
Furthermore, we test the collagen IV secretion and its organization in either 3D or 2D
differentiation through immunohistochemical staining assay (Figure. 13). The addition of LN or
FN and the mixing of LN, FN, VN to the collagen solution when fabricating the scaffolds led to
the depositing of more collagen IV to the ECM within the scaffolds (Figure. 13). In addition, a
more denser fibrillar structure that was observed in cell clusters formed within scaffolds. In 2D
culture, we also observed few col IV expressions around the cells; however, the distribution of
collagen IV on 2D culture did not display distinct structure and just deposited on the periphery of
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cells membrane. Because matrigel, which was used to coat cell culture plate before seeding cells,
contains some collagen IV protein, so the expression of col IV on 2D culture may also probably
came from Matrigel, not the DE cells secreted.

Discussion
The use of ES cells in combination of with scaffolds holds invaluable promises for
engineering all kinds of 3D tissues or organs for transplantation. Nevertheless, the understanding
of knowledge on mechanisms underlying ES cell development and differentiation in a 3D
environment is crucial to meeting this challenge. It is widely recognized that ECM plays an
important role in regulating stem cell differentiation [197]. Here, we designed a novel in vitro
culture system by utilizing collagen scaffolds combined with ECM proteins to provide a robust
hESC DE differentiation system, which may further improve the differentiation efficiency and
maturation of DE lineage cells such as insulin-producing β cells.
Successful derivation of β-cells from hESC largely depends on the efficient generation of
DE population. hESCs were able to differentiate into DE by the addition of Activin A but only in
the presence of low FBS [105]. The possible reason could be FBS contains in insulin-like growth
factor (IGF) which was known to activate PI3K in hESCs. In our experiments, Activin signaling
was able to augment DE differentiation when PI3K activity is inhibited. This result was
consistent with other’s work [107, 109]. Also, there are several critical parameters that influence
the effect of wortmannin on DE differentiation. Although wortmannin at concentration between
25 nM and 50 nM works effectively, when wortmannin was used below this level, the efficiency
of DE formation diminished, presumably because PI3K is not effectively inhibited. Also, when
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wortmannnin was used a higher concentration (> 50 nM), we saw a concentration-dependent
increase in cell death consistent with the role for PI3K in cell survival. This suggested that
different thresholds of PI3K signaling in hESCs are responsible for different cell fate outcomes.
Here, the hESCs were cultured under collagen-ECM scaffolds, particular in combination
with adhesive proteins, such as FN, LN and VN. The effect of the ECM proteins on the
differentiation of hESCs into DE cells was evaluated through the observation of cellular
morphologic and protein and molecular genes assays. As shown in Figure 1., multicellular
clusters were formed and expanded in size along with some outgrowth and cluster-cluster
connection, but not in cells cultured under two-dimensional conditions. Furthermore,
immunostaining, flow cytometric and gene expression assays revealed that the cells retained
characteristics of definitive endoderm development.
We speculate that the ECM may have enhanced the efficiency of cell differentiation in
several ways. First, there may have some direct signaling from the ECM itself, promoting
attachment and migration through porous structure. From the bright field and SEM images, the
results showed the cells were proliferated and migrated to form clusters during the culture period.
Also, the real time RT-PCR results demonstrated that by adding additional ECM proteins like
fibronectin, laminin, and vitronectin together in collagen I scaffolds, the DE differentiation
efficiency was further improved. These findings are consistent with our earlier report that a
collagen scaffold can be used as an attractive model to differentiating pancreatic β cells.
In addition, the 3D tissue formation during DE differentiation facilitated by the 3D ECM
may promote cell-cell signaling that controls the interactions among cells, a clear advantage of
3D over 2D system. A 3D environment, in which each cell is surrounded by similar cells, may
reinforce chemical signals that each cell experiences from its neighbors, helping synchronize and
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promote differentiation of the entire cell population. More than 90% of cells derived from our 3D
cultures were SOX17 positive. As such, our data indicates that compared to individual ECM
proteins, ECM protein mixture better promotes cell to cell and cell to ECM interaction resulting
in improved differentiation.
In summary, we herein described a new model to culture and differentiate hESCs in 3D
culture conditions. The combination of scaffolds with ECM molecules, in the presence of
appropriate soluble signals, results in higher DE differentiation efficiency. This system may
provide an alternative strategy for generating insulin-producing cells.
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Chapter 4
Enhanced Pancreatic β cells Differentiation from Embryonic Stem Cells in 3-D Collagen IMatrigel Scaffolds
4.1. Abstract
The success in directed differentiation of human embryonic stem cells (hESCs) into
insulin-producing β cells raises new hopes for cell-based diabetes therapy. Here we reported a
highly efficient approach to induce hESCs to differentiate into mature insulin-producing cells in
a biomimic 3D collagen/Matrigel scaffold. Collagen incorporated with 35% (v/v) Matrigel was
showed to be the most optimal composition for enhanced DE differentiation as compared to 10%
(v/v) and 50% (v/v) Matrigel and resulted in 95% SOX17-positive cells. Also, we showed small
molecular (-)-indolactam V (ILV) promoted the generation of PDX1/HNF6 positive pancreatic
progenitors when combined with other growth factors. The 3D differentiated pancreatic
endocrine cells were assembled into tissue-like structure that displayed greater similarities in
phenotype and gene expression profile to adult human islets. Our results showed that
approximately 20% insulin positive cells were generated in collagen/Matrigel scaffold as
compared to 5% in 2D culture, which correspondingly increased four-fold insulin release in
response to high glucose as compared to 2D hESCs-derived pancreatic cells. Moverover, more
mature insulin-secreting granules were observed in hESCs-derived pancreatic endocrine cells in
collagen/Matrigel scaffold than cells in 2D culture. This work clearly demonstrated the
feasibility of utilizing this novel designed biological 3D scaffold for generating mature clinically
relevant insulin-producing β cells for treatment of diabetes.
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4.2. Introduction
Diabetes mellitus has become a global epidemic with striking impacts on patients’ health,
society and economy. Islet transplantation has been suggested to be a promising therapeutic
treatment for the treatment of diabetes. Even though some improvement has been made in islet
transplantation, this therapy was not widely available due to the shortage of donor islet tissue [47]
and cell loss during islet isolation [198]. The development of unlimited number of pancreatic
insulin-producing β cells from human embryonic stem cells (hESCs) has emerged as the most
attractive alternative.
hESCs could spontaneously differentiate into insulin-producing cells, but only 1-3%
insulin-positive cells were generated among differentiated embryonic bodies [103]. In some
cases, the insulin expression from differentiated embryonic stem cells is due to artifacts of the
insulin uptake from medium [101, 102, 199]. To address these issues, a stepwise combination of
different growth factors and small molecules has been developed to generate insulin-producing β
cells, which mimicking the critical events in vivo pancreatic organogenesis by guiding cells
through stages of definitive endoderm formation, pancreatic specification, and maturation [104,
109, 200]. In these reported protocols, cells released insulin and C-peptide, expressed certain
islet transcription factors. However, these insulin-positive cells most exhibited immature islet
characteristics. For example, the insulin-producing cells generated by D’Amour et al’s five
stage protocol [104] released C-peptide in response to secretagogues, such as potassium chloride
(KCl), but they were not glucose-responsive and C-peptide content was about 50% lower than in
human islets. Also, in general the differentiation efficiency of insulin-producing cells was quite
low and the cells are mostly polyhormonal with a poorly defined phenotype [168, 200]. It has
also been reported that the hESCs-derived pancreatic progenitors transplanted into athymic nude
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rats failed to produce substantial number of beta-like cells [201]. Collectively, further efforts are
needed to not only improve the differentiation efficiency, but also promote maturation of insulinproducing from hESCs in vitro.
The common disadvantage of the most current protocols for generating insulin-producing
cells from hESCs is using conventional 2D monolayer culture, which lack of support from extracellular matrix (ECM), which plays an important role in cell grow and development. Cell-matrix
interactions have been shown to improve β-cell survival [90, 177, 202], proliferation [203, 204]
and insulin secretion [177, 205]. Yashpal et al. work showed that blocking islet-matrix
interaction by using β1 integrin antibody leads to decrease of insulin gene expression and isletcell apoptosis [206]. Collagen gel has been used as a model for culturing stem cells in threedimensional (3D) environment, which provides a condition much more similar to native tissue
ECM than two-dimensional culture dishes [207]. Specially, the collagen gel and surrounding
medium fluid constitute a soft and flexible fibrous network that supports the rounded
morphology of cells and allows cells to freely reach out and migrate and from three-dimensional
structures. However, collagen I alone was not sufficient to provide multiple cues and
sophisticated geometry and composition that existed in native ECM for synergistically
enhancement of stem cells differentiation. We therefore augmented a collagen I matrix with
Matrigel™, a commercially available preparation of basement membrane proteins comprising
laminin, collagen IV, fibronectin, heparin sulfate proteoglycans and entactin and so on. ObergWelsh, C. et al. have shown that Matrigel significantly enhanced the insulin secretion of fetal
porcine islet-like cell clusters in vitro [208]. The combination of collagen and Matrigel could
provide not only physical supports for ESCs development and differentiation, but also the
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necessary components of ECM. This method has been successfully applied to the tissue
engineering of cardiac muscle uterus, and kidney [209, 210].
Our goal in this work was to develop a scaffold to serve as a platform for robust
differentiation of insulin-producing cells from hESCs for islet transplantation. We hypothesized
that the collagen/Matrigel scaffold would support hESCs grow and enhance the differentiation of
hESCs into mature insulin-producing β cells. To test this hypothesis, we investigated the
formation of ielet-like insulin-producing cells in 3D culture by using a modified step-wise
protocol. The maturity of final differentiated cells was evaluated.

4.3. Materials and Methods
4.3.1. hESCs culture
Human embryonic stem cells (hESCs), H9 (WiCell Research Institute, Madison, MI),
ware cultured on Matrigel (BD Biosciences, Bedford, MA)--coated cell culture plates in
mTeSR®1 medium (StemCell Technologies Inc., Vancouver, BC, Canada). A solution of
1mg/ml dispase in DMEM/F12 medium was used to passage cells every 3-5 days. The cultures
were incubated at 37°C in the atmosphere supplemented with 5% CO2, with the cell culture
medium changed daily.

4.3.2. Collagen/Matrigel scaffolds preparation
Collagen type I gels were prepared at 1.5 mg/ml concentration under sterile condition by
diluting the rat tail tendon-derived collagen I solution (BD Biosciences, Bedford, MA) with 10×
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phosphate buffered saline (Mediatech, Inc., Manassas, VA), cell culture grade DI water (Thermo
Fisher Scientific Inc., Waltham, MA). The pH of the mixture was neutralized immediately to 7.4
using 1 N NaOH. To create combinational collagen/Matirgel scaffolds, growth factor-reduced
Matrigel (BD Biosciences, Bedford, MA), a solubilized basement membrane preparation, was
incorporated in collagen I solution at 10%, 35% or 50% by volume of collagen solution. The
solution were then neutralized to pH 7.4, and added into 48-well plates and incubated at 37 °C
for 1 hour to induce gelation. No cross-linking agent was used.

4.3.3. hESCs Pancreatic differentiation of on Matrigel and in Collagen/Matrigel scaffolds
H9 cells were treated with the ROCK inhibitor, Y-27632, in cell culture medium for 2
hours before dissociating. After incubating with AccutaseTM (StemCell Technologies Inc.), cell
suspension was obtained after pelleted and resuspended in addition of mTeSR®1 medium. For
3D cultures, 10% volume of cells suspension (1.2×106 cells) was mixed with each 0.5 ml
collagen I solution with or without different concentration of Matrigel. The cell-matrices solution
was added to a 24-well plates (BD Biosciences, San Jose, CA), resulting in an initial radius of 8
mm and a thickness of 2.5 mm. The 3D constructs were placed in incubator at 37 °C for 1 hour
for gelation. Once the gels had set, 0.5 ml of cell media was added to the top of the gels and the
matrix was returned to the incubator. Moreover, two-dimensional culture was prepared for
comparison by culture H9 cells directly on the top of Matrigel-coated culture plate. The cells
were allowed to grow in scaffold or on Matrigel in mTeSR medium supplemented with 10 µM
Y-27632 for 24 hours for attachment and proliferation. A modified step-wise protocol, which is
similar to Zhang et al’s approach but with some modifications, was carried out for hESCs
pancreatic differentiation (Figure 14).
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4.3.4. Scanning electron microscopy
For SEM, 3D matrices were washed with PBS to remove proteins in the culture medium
or other impurities and then fixed overnight in 2.5% (v/v) glutaraldehyde (Electron Microscopy
Sciences, Hatfield, PA) at room temperature. After fixation, the matrices were thoroughly
washed off the fixative with distilled water. Then, samples were snap frozen in liquid nitrogen (196°C) and broken with cold forceps. A fragment of the frozen gel was transferred into a
chamber of freeze dryer for low-temperature (-100°C) high-vacuum dehydration. Dried samples
were mounted on SEM sample stages using carbon tape and sputter-coated with gold-plutonium
(palladium) alloy (Pd/Au) to a thickness of 6 nm under vacuum using a Palaron SC7620 sputter
coater (Watford, UK). Samples were then analyzed by Jeol Field Emission SEM (JSM-6335F,
JEOL USA, Peabody, MA) using a low-vacuum mode (0.75 Torr), at 10kV accelerating voltage
and 7.7mm working distance.

4.3.5. Quantitative real-time polymerase chain reaction
Cell-scaffold constructs were mechanically homogenized with a Tissue-Tearor (BioSpec
Products, Bartlesville, OK) while cells cultured on Matrigel-coated tissue culture plate were
harvested with a cell scraper. Total RNA was extracted from cultured cells using an RNeasy Plus
Mini kit (Qiagen, Valencia, CA) after Prior to reverse transcription (RT), RNA samples were
digested with DNase I to remove contaminating genomic DNA. Reverse transcription was
performed with 1 µg of total RNA using High Capacity cDNA Reverse Transcription Kit
(Invitrogen) followed by the manufacture’s instruction. Real-time quantitative PCR was carried
out using the Power SYBR Green PCR master mix (Applied Biosystems) and was performed on
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the Realplex Real-Time PCR system (Eppendorf, Realplex4 model). Initial enzyme activation
was performed at 95 °C for 15 min, followed by 40 cycles of denaturation at 95 °C for 15 s, and
primer annealing/extension at 60 °C for 1 min. Melting curve analysis was performed at 95 °C
for 1 min, 60 °C for 30 s and 95 °C for 30 s. Primer’s sequences are given in table 1. The
expression levels of target genes were normalized against endogenous control β-actin. All
samples were analyzed in triplicates.

4.3.6. live/dead cell staining in 3D collagen/Matrigel scaffolds
The cell viability within scaffolds was determined using live/dead cell double staining kit
(Sigma-Aldrich, Saint Louis, MO). Cell-scaffold 3D constructs were incubated with 200 µl
live/dead staining solution at 37oC for 15min by following the manufacture’s instruction. The
excess dye solution was removed and 0.5 ml of PBS was added on the top of the gel. Excess
buffer was subsequently removed in order to stabilize the cell containing scaffolds sample for
imaging. Samples were examined by using the Olympus upright microscope (IX71, Tokyo,
Japan) equipped with a supersensitive CCD camera (mode number ROLERA-XR, Surrey, BC,
Canada) controlled by an imaging analysis software Slidebook (Intelligent Imaging Innovations,
Inc., Denver, CO).

4.3.7. Immunofluorescence staining
Scaffold-embedded cells were fixed in 4% paraformaldehyde for 15 min and washed 3
times with PBS. Permeabilization was performed with 0.1 Trixton X-100 for 5 min.
Cryosectioning of scaffolds was performed as described elsewhere [196]. Briefly, Scaffold-cell
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constructs were fixed in 10% neutral-buffered formalin solution (NBF) for 3 hours. After
overnight infiltration with a series of 20% sucrose and sucrose/OCT® solution, the scaffolds
were placed in a peel-away mold (VWR, south Plainfield, NJ) in tissue freezing medium (TissueTek OCT Compound, Sakura-Fintek). All the molds were then placed into the MICROM
cryostat (Richard-Allan Scientific) chamber and the samples were allowed to freeze at -20oC for
at least 30min. Routine frozen sectioning was performed by collecting 8-µm sections onto
positively charged slides. The scaffold sections were either collected or air dried for a minimum
of 30min. Before staining, sections were hydrated in PBS for 10min and then permeabilization
was performed with 0.1 Trixton X-100 for 5 min. then incubated in blocking buffer (PBS
containing 5 % normal goat serum, 0.3 % Triton X-100) for 1 h and thereafter nonspecific
antibody binding was blocked by 10% normal serum from the species in which the secondary
antibodies were raised. Cells were incubated with primary antibodies overnight at 4 °C followed
by secondary antibody incubation for 1 hour at room temperature. To stain 2D cultures, cells
seeded on Matrigel-coated plates were fixed with 4 % paraformaldehyde (Sigma). After treated
in blocking buffer to inhibit unspecific labeling (45 min at room temperature), cells were labeled
with primary and secondary antibodies as described above. DAPI (Research Organics) were used
to counterstain the nucleus. Images were captured under an inverted fluorescence microscope
(Olympus, IX71, Japan). The primary antibody and secondary antibody are described in Table 1.

4.3.8. Flow cytometry
For 3D culture, hydrogels were digested with 2mg/ml collagenase solution (Life
Technologies) for 30min at 37oC. After centrifugation at 300x g for 5min and aspiration of
supernatant, the cells were then treated with 0.25% typsin with EDTA (sigma) to further digest
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the cells into single cell suspension. Cells were filtered through 70mm cell strainer (BD
FalconTM) to removes the clumps. For 2D culture, cells were dissociated using AccutaseTM cell
detachment solution (Millipore) for 5 min followed by removal of trypsin by centrifugation.
Cells were then fixed with 4% paraformaldehyde and permeabilized with ice-cold methanol.
Cells were labeled with PE mouse anti-human Sox17 (BD Biosciences) at 5 µl per 1 × 106 cells
or mouse anti-human Insulin (Cell signaling Technology, Inc.) for 45min at room temperature in
the dark. Cells labeled with PE mouse IgG1ĸ was used as isotype control. Cells were washed
three time and resuspended in PBS with 10% inactivated FBS and 0.09% sodium azide. Samples
were acquired on a BD fluorescence activated cell sorter (FACS) Calibur flow cytometer
(Becton-Dickinson Biosciences, Franklin Lakes, NJ) and data analyzed using Bection-Dickinson
CellQuest software (BD Biosciences).

4.3.9. Glucose stimulated insulin secretion assay
To determine if cells at the end of differentiation were capable of glucose-stimulated
insulin release (GSIR), cells in 2D and 3D culture were washed three times with Krebs-Ringer
buffer containing 0.1% BSA and 10mM HEPES and first incubated with Krebs-Ringer buffer
free of glucose for 60 min at 37°C. Afterward, every dish was exposed to Krebs-Ringer buffer
containing 5.5 mM, 15 mM or 25 mM glucose for 90 min at 37°C. Supernatant were then
collected and insulin level were measured by using an Insulin ELISA kit. The amounts of insulin
secretion were normalized by measuring total intracellular protein using BCA™ protein assay kit
(PIERCE). Each experiment was triplicated performance.
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4.3.10. Transmission electron microscopy (TEM)
2D cells and 3D matrices were fixed in 3% glutaraldehyde in 0.1 M cacodylate buffere
(pH 7.4) for 2 hours at room temperature. After rinsing in 0.05 M cacodylate buffer, samples
were post-fix in 1% osmium tetroxide for 2 hours and rinsed with distilled water. After prestain
overnight in 0.5% uranyl acetate at 4 °C, samples were dehydrated through a graded ethanol
series to 100%, rinsed in propylene oxide and embedded in Spurr’s epoxy. 80 nm thick sections
were cut on a MT2-B ultramicrotome and stained in 2% uranyl acetateand lead citrate. Samples
were examined using a Philips EM 410LS TEM operated at 80 kV.

4.3.11. Statistical analysis
All experiments were carried out at least in triplicate. Unless otherwise indicated in the
text, all analytical measurements were repeated three times. All data were expressed as means ±
standard deviations. Statistical analysis was performed with Student’s t-test, with p<0.05
considered as statistically significant.

4.4. Results
4.4.1 Scaffold morphology
The incorporation of various concentration of Matrigel in collagen scaffold affects the
microstructural features. SEM images of these collagen/Matrigel scaffolds exhibited welldefined, interconnected pore structures (Figure 15). In these constructs, 10% Matrigel constructs
appeared less interconnected and less uniformly distributed. As the percentage of Matrigel
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increased to 35% and 50%, the relative homogeneity of these scaffold morphological features
can be appreciated, with more tightly packed fibrils and smaller pores. It was evident that the
increases of Matrigel concentration gave rise to a subststaintial decrease of both void and
interconnect size.

4.4.2. Effect of Matrigel on the hESCs definitive endoderm differentiation
To examine the effect of Matrigel on the efficiency of hESCs differentiation into
pancreatic cells, hES cells were seeded into 1.5 mg/ml collagen gel incorporated with 10%, 35%
or 50% (v/v) of Matrigel respectively. DE differentiation was implemented for 4 days and cells
were harvested at the end of this stage for analyzing the expression of DE marker genes. As
shown in Figure 16A, the incorporation of Matrigel in collagen gel significantly improved the
expression level of DE genes such as Sox17, Foxa2 and CXCR4 compared to hESCs
differentiated on 2D Matrigel substance. Among the three different scaffolds, 35% Matrigel
showed the best effect on the enhancement of DE differentiation, which improved Sox17, Foxa2,
CXCR4 expression by 35-fold, 22-fold, 10-fold respectively, which was 2-3 fold increases
compared to cells differentiated 10% or 50% (v/v) Matrigel constructs. Corresponding to the
qRT-PCR results, flow cytometry was used to analyze the Sox17 positive population in the
differentiating cells on day 4. As showed in Figure 16B, 95% of cells are identified Sox17+ in 35%
Matrigel as compared to 73% Sox17+ in 10% Matrigel and 85% Sox17+ in 50% Matrigel. This
was in good agreement with the gene expression profile.
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4.4.3. The morphological and viability analysis of hESCs pancreatic differentiation in
collagen/Matrigel scaffolds
To compare the morphological changes of differentiating cells cultured under two- and
three-dimensional conditions, undifferentiating single cells were seeded on Matrigel-coated cell
culture plates or in 35% Matrigel/Collagen scaffolds and cell morphology was observed by
phase-contrast microscopy at day 4 and day 10. Cells under 2D and 3D culture all proliferated
rapidly, however, the morphology of cells differed greatly (Figure 17). In monolayer culture, the
cells lost classical hESCs morphology and present a confluent monolayer with uniform
morphology of flat, polygonal shape on day 4 of pancreatic differentiation, which showed overt
differentiation. Upon the differentiation process, the cell cultures were densely packed and
formed some tightly packed aggregates on day 10 of differentiation. In the collagen/Matrigel gel
culture system, a number of newly formed cell clusters appeared by cell proliferation,
homogenously distributed as shown by phase contrast microscopy. The size of the clusters grew
over time, resulting in spherical shapes with densely packed cells at day 10. Also, the outgrowth
of cells from the periphery of most clusters was observed and cells formed tissue-like structures,
indicating the initiating of hESCs differentiation. The viability of cells in 3D collagen/Matigel
culture was determined by calcein-AM/PI live/dead cell staining. Almost all the cells in 3D
culture were viable, and the viability remained high (approximate 98% viable cells) even after 10
days of differentiation (Figure 17F). These results suggested that the 3D collagen/Matrigel
culture system developed in this study provided a suitable cell housing microenvironment for
hESCs proliferation and differentiation.

4.4.4. ILV treatment promoted the generation of pancreatic progenitor cells
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In order to promote the commitment of hESCs differentiation into PDX1-expression
progenitor cells, a small molecular (-)-indolactam V (ILV) was combined with growth factors
reported to be involved in pancreatic development, including retinoic acid (RA), FGF7 and
noggin. ILV was found to be able to specifically induce pancreatic progenitors from definitive
endoderm. We found that the addition of ILV at stage II resulted in increase of gene expression
of pancreatic progenitor markers including PDX1, SOX9, and HNF6 by 20-fold, 16-fold, and 63
fold respectively, on day 8 of pancreatic differentiation (Figure 18B). Consistent with the gene
expression analysis, immunostaining revealed that larger population of cells were stained both
PDX1 and HNF6 positive in the culture that treated with ILV compared to non-ILV treatment
control, which indicated the importance role of ILV signaling in pancreatic progenitor generation.
Specifically, the 3D structure of pancreatic progenitors was observed in 3D collagen/Matrigel
culture system after 4 days of ILV treatment along with other growth factors for pancreatic
progenitor differentiation.

4.4.5. Immunohistochemical characterization of hESCs-drived insulin-producing cells in
collagen/Matrigel scaffold
To obtain insulin-producing cells in vitro, the stage 3 EP cells were incubated with
exendin-4, nicotinamide, BMP4 and bFGF for 7 days. As shown in Figure 19, at the end of
differentiation in this experiment, insulin-producing cells were observed, and these cells tent to
be organized into a 3D islet-like structure. Also, the insulin-producing cells co-produced Cpeptide, a by-product from proinsulin process, indicating the de novo endogenous insulin
production, as opposed to uptake from the culture medium. As an essential regulation of
pancreatic development, the expression of PDX1 was also observed, with co-expression of
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NKX6.1 and NGN3, which confirmed their pancreatic β cell characteristics. Within the 3D
cellular architect, the endocrine hormones that secreted from pancreatic α, δ and PP cellsglucagon, somatostatin and pancreatic polypeptide were detected in a small number of cells,
which is consistent with the hormone expression pattern of mature islets. These results indicate
that hESCs can be differentiated into insulin-producing cells through a four-stage protocol and
organized into islet-like 3D structure in the developed collagen/Matrigel scaffold.

4.4.6. Gene expression profile of hESCs-derived insulin-producing cells in 2D and 3D
The expression pattern of pancreatic markers in 2D and 3D culture throughout
differentiation was monitored by quantitative real-time PCR. As illustrated in Figure 20, the
expression peak of Sox17 was observed at the end of stage I and the expression level in cells
cultured in collagen/Matrigel 3D culture was enhanced by 14 folds compared to cells in 2D,
indicating the enhancement of definitive endoderm differentiation in 3D culture. The expression
of PDX1 and NGN3 emerged at stage II and reached the peak at the end of stage III, suggesting
pancreatic specialization. The data showed that the enhancement of PDX1 and NGN3 expression
in collagen/Matrigel scaffold compared to 2D culture persisted throughout the differentiation
process. In addition, we observed enhanced Insulin gene expression in Collagen/Matrigel
scaffold at each time point and reached the peak at the end of stage IV differentiation, which
resulted in 5 fold increase as compared to cells cultured in 2D. Glut2 is a glucose transporter
found in the cell membrane of mature β-cells and is not only an important indicator of β-cell
maturity but also is required for glucose-induced insulin release. Glut2 gene expression level was
enhanced in 3D culture at each time point or compared to 2D culture values. Additionally, MafA
gene expression is a hallmark of fully differentiated pancreatic endocrine cells. Our data showed
69

that MafA gene was upregulated along with the process of pancreatic differentiation process
increased 5 folds compared to 2D culture at the end of differentiation.

4.4.7. Insulin secretion in 2D and 3D culture
The biological function of hESCs-derived insulin-producing cells β cells in 2D and 3D
culture were determined by insulin secretion upon glucose challenges (Figure 21A). A nearly
4.5-fold and 7 fold increase in insulin secretion from 3D induced cells were observed when cells
were incubated in 15 mM and 25 mM high glucose-containing medium, in comparison with
buffer containing lower glucose concentration (5.5 mM). Conversely, only 2.8-fold and 3.7 fold
increase in insulin secretion was detected in 2D induced cells when they were incubated in 15
mM and 25 mM high glucose-containing medium. Approximately, 44 ± 4.9 µIU insulin/mg
cellular proteins were secreted from 3D-induced cells in high glucose (25 mM)-containing
medium, whereas only 10.8 ± 3.2 µIU insulin/mg cellular proteins from 2D-induced cells. This
represents an approximate four-fold increase in 3D-induced cells compared to 2D-induced cells
when cells challenged with high glucose concentration. These results indicate that 3D inducedinsulin producing cells are more sensitive to a glucose challenge due to their improved maturity.
Furthermore, we analyzed the percentage of insulin+ cells by using flow cytometry. After
approximate 21 days of pancreatic induction, the insulin-positive cells were reached
approximately 20% in 3D collagen/Matrigel culture, compared to 5% in 2D. It suggested 3D
culture not only promote the maturity of hESCs-induced β cells, but also enhanced the
production of insulin-section cells in a higher population.
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4.4.8. Ultrastructural characteristics of hESC-derived pancreatic cells
We used transmission electron microscopy to determine whether the hESCs-derived cells
formed mature secretory granules. The typical mature insulin granules were observed in 2D and
3D induced cells (Figure 22), which is characterized by round electron-dense crystalline core
surrounded with the distinctive large, clear halo. The inner crystalline core of insulin granule is
less electron opaque in mature β cells than those found in glucagon-containing and somatostatincontaining α- and δ- cells, which confirmed the generation of insulin-producing β cells. The
granule number was approximately 12 times fewer in 2D-induced cells than in 3D-induced cells
as counted from 5 individual cells from each sample.

4.5. Discussion
Current protocols for stem cell differentiation mainly rely on mimicking the sequence of
signaling events that underlies the differentiation of tissues in embryological development. Apart
from specific soluble growth factors for lineage specific differentiation, the importance role of
ECM on stem cell differentiation is greatly ignored. In this study, we established a new model
for hESCs differentiation and we demonstrated that more mature insulin-producing cells can be
generated from hESCs with higher efficiency in the designed three-dimensional culture system.
Collagen I hydrogel is mechanical robust and easy to handle, which is of practical
importance when translate their use as engineered tissues in the clinic. In addition, the main
ECM of mature human islets has most often been reported to be composed of laminin and
collagen IV [185]. Therefore, it is possible that the addition of Matrigel allows hESCs to
preferentially attach to the properties of their native environment and perform the differentiation
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close to in vivo development in the composite matrices that developed in this study. Recent
studies in stem cell biology revealed that when exposed to the intrinsic properties of the
extracellular matrix, such as matrix structure, elasticity, and composition, stem cells can
differentiate into various lineage of mature tissue cells [149]. Incorporation of Matrigel in
collagen gel can cause distinct changes in the constructs morphologies and mechanical properties
Thus, in this study; we incorporated Matrigel at different ratio (10% v/v, 35% v/v or 50% v/v) in
collagen gel and tried to figure out the preferred condition for pancreatic differentiation. The
changes in fibrillar structure were confirmed by SEM. At low Matrigel concentration (10% v/v),
the matrix structure was uniform with a fine fiber structure, whereas at higher percentages of
Matrigel, larger fibrils appeared with uniform pore size. Also, the mechanical properties differed
in various collagen/Matrigel scaffolds has been reported [211]. The higher concentration of
Matrigel incorporated in collagen gel resulted in increased Young’s moduli of the various
collagen-Matrigel compositions[211]. The differences in architectural and mechanical properties
of collagen/Matrigel scaffolds were related to stem cell differentiation efficiency. Our data
showed that 35% Matrigel gave rise to the highest expression of definitive endoderm gene, such
as Sox17, Foxa2 and CXCR4. The efficient generation of DE cells would facilitate the following
differentiation step. Thus, the collagen gel incorporated with 35% Matrigel was used in other
experiments.
Another factor that may contribute to expansion and maturation of insulin-producing
cells in 3D culture is the use of growth factors and small molecules. Activin A has been used to
induce DE cells in most reports. However, recently study by Mclean et al. showed that Activin A
efficiently specified DE differentiation from hESCs only when phosphatidylinositol 3-kinase
(PI3K) signaling is suppressed [107]. In this study, wortmannin, a PI3K inhibitor, was used for
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DE induction and it showed 95% of cells in collagen/Matrigel (35% v/v) scaffolds were Sox17
positive. For differentiation of DE cells into pancreatic progenitors, the combinational use of
Noggin, an inhibitor of bone morphogenetic protein (BMP) signaling, retinoic acid, and
fibroblast growth factor 7 (FGF7 or KGF), which were reported to induce pancreatic progenitor
cells generation in our studies [106, 212-214], was applied in our protocol. In addition, by using
high-content screen in a chemical library of 5,000 compounds, (-)-indolactam (ILV) was
identified to induce PDX1-positive pancreatic progenitor cells at high efficiency [215]. Here, we
included small molecule ILV in the growth factor regimen and found out that with the addition
of ILV, the pancreatic progenitor markers PDX1, HNF6 and Sox17 were increased dramatically
compared to cells treated without ILV. The induction of insulin-producing cells was
characterized at the final stage. As revealed by immunohistochemical staining, the cluster formed
in 3D culture consist as lease three types of cells, including insulin-producing β cells, glucagonsecreting α cells and somatostatin-secreting δ cells, suggesting the expression pattern of mature
islets. Moreover, the co-expression of Insulin, C-peptide, PDX1 and NKX6-1 was observed in
the induced insulin-producing cells in 3D culture, which is considered to be a specific functional
characteristic of mature β cells [216]. The quantitative PCR-based gene expression profiling
demonstrated that β-cell specific transcription factors including PDX1, NKX6-1, Insulin and
Glut2 were significantly increased in the 3D culture and presented a closer gene expression
pattern to human pancreas development. Furthermore, the maturation phenotype of insulinproducing was confirmed. For example, the 3D-induced cells can secrete insulin in response to
glucose stimulation in a more sensitive manner, and the insulin-positive cells comprised about 20%
of population at the final stage. Furthermore, the insulin-containing granules were detected as a
symbol of mature β cells.
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To summarize, in this work we established a novel 3D model to induce hESCs
differentiate into mature insulin-producing cells that demonstrated more close phenotype and
gene expression profile to adult human islets. We believe this presented strategy would not only
provide an efficient method to use hESCs for clinical-relevant application, but also facilitate the
future study of the mechanism of human pancreatic specialization and maturation in vitro.
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Chapter 5
Conclusion and Future Directions
In this work, we have established a novel 3D culture system by using nature ECM
proteins for pancreatic lineage differentiation from hESCs. We believe the data presented in this
study offered direct evidence supporting the hypothesis that 3D pancreatic differentiation of
hESCs may represent a valuable technique for generating clinically relevant β cells in vitro.
These work provided a proof-of-concept study and this method can be transformed to generate
other lineage specific tissue from ESCs such as hepatocyte and neural cells.
The main goal of directing the differentiation of hESCs to β cells is to provide a new
source of β cells for transplantation therapy. Due to the interesting findings, in order to further
characterize the maturity of hESCs-induced insulin-producing cells, our future research may lead
to perform an animal study to further test their ability to maintain blood glucose levels following
transplantation. hESCs-derived β cells can be transplanted into mouse kidney capsule, and
function of β cells can be determined by the insulin and glucose concentrations in serum after
challenging with high glucose. A rapid glucose-responsive insulin release following
transplantation is highly desired. Creating functional, adult-like β cells in vitro may require
further understanding of β cell metabolism, the role of islet structure, the pathways or molecules
involved in 3D niches for pancreatic specification.
The development of microscale techninologies offers powerful tools for stem cell study
and tissue engineering [217]. Scaffold can be fabricated at microscale and nanoscale by the use
of 3D printing, microsyringe deposition, and electronspinning of nanofibers. These techniques
allow control of cellular microenvironment in vitro and provide templates for cell aggregate
formation or perform high-throughput assays. We anticipate that the use high-throughput
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screening methodologies will contribute to the design of new 3D scaffolds for the expansion and
lineage-specific differentiation of hESCs. In addition, understanding other limitations of 3D stem
cell culture may provide guidance for more efficient generation of lineage specific cells. For
example, vascularization is the capstone in large-scale tissue-engineering application [218].
Recent findings suggested that co-culture β cells with microvascular endothelial cells help
maturation of hESCs differentiation into β cells [219]. Therefore, development of a 3D patterned
co-culture system in regulating various aspects of cellular microenvironment would be an
imperative direction for complete maturation of pancreatic β cells generated from human
pluripotent stem cells.
Reproducibility of results across hESCs line is of critical importance for stem cell
research. Recently, much attention have been given to the description and explanation of
differences between various hESCs lines [220]. These differences result in large variations in
propensity of differentiation between cell lines. The data obtained in this study on based on H9
cell line acquired from Wicell. Although H9 cell line have been widely used in hESCs
differentiation, the adaptation of this technique in other pluripotent stem cell lines may be
necessary.
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Table 1. List of PCR primers
Gene
SOX17
FOXA2
CXCR4
OCT4
PAX6
N-CAD
BRACH
SOX3
FN1
LAMC1
Col4A1
COL3A1
COL1A1
COL1A2
SOX9
HNF6
PDX1
NGN3
INSULIN
MAFA
GLUT2

Sequence
5’-GGCGCAGCAGAATCCAGA-3’
5’- CCACGACTTGCCCAGCAT-3’
5’-GGGAGCGGTGAAGATGGA-3’
5’-TCATGTTGCTCACGGAGGAGTA-3’
5’-CACCGCATCTGGAGAACCA-3’
5’-GCCCATTTCCTCGGTGTAGTT-3’
5’-TGGGCTCGAGAAGGATGTG-3’
5’-GCATAGTCGCTGCTTGATCG-3’
5’- TCTCCTCCATCAACCGAGTC-3’
5’- GAGCCACTATGGGGAGTGAG-3’
5’-CCCACACCCTGGAGACATTG-3’
5’-GCCGCTTTAAGGCCCTCA-3’
5’-TGCTTCCCTGAGACCCAGTT-3’
5’-GATCACTTCTTTCCTTTGCAGTT-3’
5’-CCCAGCCTACAAAGGTGAA-3’
5’-CCCAGCCTACAAAGGTGAAA-3’
5’- CCCATCAGCAGGAACACCTT-3’
5’- GGCTCACTGCAAAGACTTTGAA-3’
5’-TGGGCATTCTTCTGTCTGTACAA-3’
5’- GCCACCCATCCTCATCAATC-3’
5’-ACTCTTTTGTGATGCACACCA-3’
5-AAGCTGTAAGCGTTTGCGTA-3’
5’-AACACGCAAGGCTGTGAGACT-3’
5’-GCCAACGTCCACACCAAATT-3’
5’-GAACGCGTGTCATCCCTTGT-3’
5’- GAACGAGGTAGTCTTTCAGCAACA-3’
5’-AAGGTCATGCTGGTCTTGCT-3’
5’-GACCCTGTTCACCTTTTCCA-3’
5’- AGACCTTTGGGCTGCCTTAT-3’
5’- ACTTGTAATCCGGGTGGTCCTT-3’
5’- TGTGGAAGTGGCTGCAGGA-3’
5’- TGTGAAGACCAACCTGGGCT-3’
5’- AAGTCTACCAAAGCTCACGCG-3’
5’- GTAGGCGCCGCCTGC-3’
5’-CCCTCTACTCCCCAGTCTCC-3’
5’-CCTTACCCTTAGCACCCACA-3’
5’-GCAGCCTTTGTGAACCAACAC-3’
5’-CCCCGCACACTAGGTAGAGA-3’
5’- CTTCAGCAAGGAGGAGGTCATC -3’
5’- CTCGTATTTCTCCTTGTACAGGTCC -3’
5’- GCTACCGACAGCCTATTCTA-3’
5- CAAGTCCCACTGACATGAAG-3’
77

Product
(bp)

Annealing
temperature (°C)

102

61

82 bp

60

86 bp

62

92 bp

62

151 bp

60

96 bp

60

112 bp

61

102 bp

60

82 bp

60

86 bp

60

151 bp

60

88 bp

60

91 bp

62

115 bp

60

121 bp

60

131 bp

60

199 bp

60

114 bp

62

147 bp

62

208 bp

62

267 bp

62

Table 2. List of Antibodies used in immunocytochemisty and immunohistochemistry
Antibodies

Host

Dilution or
Concentration

Producer

Anti-Sox17

Mouse

1:50

R&D Systems

Anti-Foxa2

Rabbit

1:1000

Abcam

Anti-Pdx1

Rabbit

1:2000

Abcam

Anti-Collagen IV

Rabbit

1:200

Abcam

Anti-HNF-6

Mouse

1:200

Santa Cruz Biotechnology, Inc.

Anti-Nkx2.2

Mouse

2 µg/ml

Developmental Studies
Hybridoma Bank

Anti-Ngn3

Mouse

2.5 µg/ml

Developmental Studies
Hybridoma Bank

Anti-Nkx6.1

Mouse

3 µg/ml

Developmental Studies
Hybridoma Bank

Anti-Insulin

Rabbit

1:400

Cell Signaling Technology,
Inc.

Anti-Glucagon

Mouse

1:4000

Millipore

Anti-C-Peptide

Mouse

1:100

Millipore

Anti-Somatosatatin

Rat

1:100

Millipore

Anti-Pancreatic polypeptide

Mouse

1:50

R&D Systems

TRITC-conjugated antirabbit IgG

Donkey

1:100

Jackson ImmunoResearch

Alexa Fluor®-conjugated
anti-rat IgG

Donkey

1:500

Jackson ImmunoResearch

DyLight™ 488-conjugated
anti-mouse IgG

Goat

1:500

Thermo Scientific

PE anti-human Sox17

Mouse

1 ug/ml

BD Biosciences

PE IgG1 ĸ isotype control

Mouse

1 ug/ml

BD Biosciences
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Figure. 1. Morphological changes and expression of pluripotent markers of hESCs before
differentiation. (A-F) Phase-contrast microscopy images of hESCs cultured on MEF feeder
layers (A-C) or MatrigelTM (D-F). hESCs proliferated from day 2 (A, D), day 3 (B, E) to day 4 (C,
F). (G-I) Immunocytochemical analysis of pluripotency in H9 hESCs. Cells were stained with
antibodies against pluripotency marker proteins SOX2 (G), SSEA4 (H), and TRA-1-60 (I) after
five passages. Cells were also labeled with diaminophenylindole (DAPI) in order to localize the
nucleus. Stained cells were observed under a fluorescence microscope (Olympus IX 71)
equipped with a CCD camera. Scar bar (A-C, G-I) 50 µm, (D-F) 300 µm.
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(A)

(B)

Figure. 2. Scanning electron microscopy (SEM) images of the collagen I scaffold. (A)
Micrographic structure of 1.5 mg/ml collagen I scaffold. (B) hESCs integrated in collagen
scaffold. Scale bar: 2µm.
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Figure. 3. Morphological and viability analysis of hESCs-derived definitive endoderm in 3D
collagen cultures. hESCs were seeded into a 3D collagen scaffold (1.5mg/ml) as single cells (A,
B, E, F) or cell clusters (C, D, G, H) in a 24-well plate (2.5×106 cells/ml). A-D: Bright field
images of hESCs on day 2 (A, C) and day 4 (B, D) of DE differentiation in 3D cultures. E-H:
hESCs proliferated and maintained a high viability on day 2 (E, G) and day 4 (F, H) as
determined by live/dead cell staining. Scale bar: 30 µm.
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Figure. 4. hESCs proliferation in 3D collagen scaffold. hESCs were seeded in collagen scaffold
as single cells or cell clusters and time course of cell proliferation was performed by Alamarblue
assay from day 0 to day 5. Fluorescence intensity was detected at excitation wavelength of 570
nm and fluorescence emission at 590 nm. Data were the measurements in triplicate experiments
at indicated time intervals.
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Figure. 5. Quantitative PCR analysis of DE marker genes and other germ layer marker genes of
hESCs-induced DE cells after 4 day of differentiation by using single cells inoculation method or
cell clusters inoculation method. Undifferentiated hESCs were served as control and the mRNA
levels were normalized to β-actin
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Figure. 6. Comparison of DE differentiation efficiency by culture hESCs in DE differentiation
medium A (Activin A and Wnt3a) or medium B (Activin A and wortmannin). (A) Quantitative
PCR analysis of DE and three germ layers marker genes expression of hESCs-induced cells on
day 1, day2 and day4 of DE differentiation. Expression levels were normalized to β actin. (B)
Flow cytometric analysis of SOX17 positive cells in hESCs-induced cells on day 4. (C)
Immunofluorescence staining of SOX17 (red), FOXA2 (green) in hESCs-induced cells on day 4.
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Figure. 7. Bright field microscopy images of hESCs-induced cells in 2D and 3D ECM scaffolds.
hESCs were induced into DE in 2D (A and B), type I collagen scaffolds (Col I, C and D), and
collagen along with laminin (LM, E and F), fibronectin (FN, G and H), vitronectin (VN, I and J)
or mixture of ECM proteins (Mix, K and L). Morphologies were observed on day 2 (left panel)
and day 4 (right panel) of DE differentiation. Scale bar (A-B) 200 µm, (C-L) 100 µm.
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Figure. 8. The viability of hESCs-induced DE cells in 3D ECM scaffolds. hESCs were cultured
into type I collagen scaffolds (Col I, A and B), and collagen I along with laminin (LM, C and D),
fibronectin (FN, E and F), vitronectin (VN, G and H) or mixture of ECM proteins (Mix, I and J)
in DE differentiation medium for 4 days. Live/dead staining were performed on day 2 (left panel)
and day 4 (right panel) of DE differentiation. Images were taken using an inverted fluorescence
microscopy Olympus IX-71. Scale bar = 200 µm.
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Figure. 9. Scanning electron microscopy of collagen scaffolds along with various ECM proteins
without (left panel) or with hESCs (right panel). The following scaffolds were presented: Col I
(A, B), Col I + LM (C, D), Col I + FN (E, F), Col I + VN (G, H), Col I + Mix (I, J). Scale bar =
2 µm.
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Figure. 10. Enhancement of DE differentiation in 3D collagen-based ECM scaffolds. (A)
Quantitative PCR analysis of hESCs-induced DE cells after 4 days of culture in 2D and 3D
collagen gel along with ECM proteins LM, FN, and VN. Relative gene expression levels in DE
cells cultured in 3D were normalized to DE cells in 2D culture and beta-actin was used as
calibration gene. (B) Flow cytometric analysis of Sox17 in definitive endoderm derived from
human embryonic stem (ES) cells. DE cells were stained with either PE Mouse IgG1, κ isotype
control (filled histogram) or PE Mouse Anti-human Sox17 antibody (open histogram) at matched
concentrations.
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Figure. 11. Immunohistochemical staining of definitive endoderm markers, Sox17 and Foxa2 in
hESCs-induced cells culture in 2D and 3D scffolds made of collagen I along with laminin,
fibronectin, and vitronectin. The definitive endoderm cells were examined after 4 days of
differentiation. The nuclei were conterstained with DAPI. Scale bar = 50 µm.
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Figure. 12. Quantitative PCR analysis of ECM gene expression of hESCs-induced DE cells in
2D and 3D culture. hESCs were induced into DE cells for 4 days in 2D or 3D collagen gel along
with various ECM proteins such as LM, FN, and VN. Relative gene expression levels in DE cells
cultured in 3D scaffolds were normalized to DE cells in 2D and beta-actin was used as
calibration gene.
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Figure. 13. Immunohistochemical staining of collagen IV secretion by DE differentiated cells in
3D scaffolds made of various ECM proteins. After 4 days of DE differentiation, cells in 2D and
3D culture were stained with rabbit anti-collagen IV primary antibody and TRITC conjugated
donkey anti rabbit secondary antibody. Nucleus was counterstained with DAPI. Scale bar=50
μm.
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Figure. 14. A modified step-wise protocol for differentiating human ES cells into insulinproducing cells. Stage I: human ES cells were induced into definitive endoderm in the presence
of activin A and wortmannin. Stage II: the differentiated endoderm cells were treated with RA,
KGF, Noggin and ILV to induce pancreatic progenitor formation. Stage III: cells were exposed
to EGF to endorse pancreatic endoderm lineage specific differentiation. Stage IV: a cocktail of
factors including nicotinamide, extendin-4, BMP4 and bFGF as utilized to promote the
maturation of pancreatic β cells (this protocol is similar to Zhang, D. et al.’s approach but with
some modification).
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Figure. 15. Scanning electron micrographs of collagen I network incorporated with various
concentration of Matrigel: (A, D) 10% Matrigel, (B, E), 35% Matrigel, (C, F) 50% Matrigel.
Scale bars: A-C, 50 µm, D-F, 10 µm.
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Figure. 16. Effect of Matrigel concentration in 3D collagen-I based scaffold on hESCs
differentiation into definitive endoderm. (A) Quantitative PCR analysis of definitive endoderm
markers of hESCs-derived DE cells after 4 days of differentiation in 2D and 3D collagen gel
along with 10%, 35%, 50% Matrigel. Expression level were normalized to β-actin. For each
sample, relative expression levels were normalized to corresponding levels in cells under 2D
culture. (B) Intracellular flow cytometric analysis of Sox17 at day 4 of DE differentiation in 2D
and 3D collagen gel along with 10%, 35%, 50% Matrigel. DE cells were stained with either PE
Mouse IgG1, κ isotype control (filled histogram) or PE Mouse Anti-human Sox17 antibody
(open histogram) at matched concentrations.
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Figure. 17. The morphology and viability of hESCs during pancreatic differentiation process in
3D collagen/Matrigel scaffolds. (A-D) Phase contrast microscopy images of hESCs pancreatic
differentiation at day 4 (A, C) and day 10 (B, D) in 2D (A, B) and collagen/Matrigel scaffold (C,
D). (E-F) Live/dead staining of hESCs-differenting cells in collagen/Matrigel scaffold on day 4
(E) and day 10 (F).
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Figure. 18. The effect of (-)-indolactam V (ILV) on the differentiation of pancreatic progenitor
from DE. (A) Immunofluorescence analysis of coexpression of PDX1 and HNF6 in hESCsinduced pancreatic progenitor cells treated with or without ILV in 2D and 3D collagen/Matrigel.
(B) Quantitative PCR analysis of pancreatic progenitor marker genes in hESCs-induced cells
treated without or with ILV on day 5 and day8. Expression level were normalized to β-actin. All
values are normalized to cells cultured on day 5 without ILV treatment.
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Figure. 19. Double immunofluorescence analysis of pancreatic cells differentiated from hESCs.
(A-C) PDX1 (A); NKX6.1 (B); merged images of PDX1, NKX6.1 and DAPI (C). (D-F) PDX1
(D); NGN3 (E); merged images of PDX1, NGN3 and DAPI (F). (G-I) Insulin (G); C-peptide (H);
merged images of insulin, C-peptide and DAPI. (J-L) Insulin (J); Somatostatin (K); merged
images of insulin, somatostatin and DAPI. (M-O) Insulin (M); polypeptide (N); merged images
of Insulin, polypeptide and DAPI. (P-R) Insulin (P); glucagon (Q); merged images of insulin,
glucagon and DAPI (R).
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Figure. 20. Quantitative PCR analysis showed the dynamic expression of several key genes
during hESCs-induced pancreatic β cell development. Cell samples were collected at the end of
stage I, stage II, stage III, and stage IV. mRNA of hESCs-induced cells at stage I in 2D culture
was used as control to normalize gene expression level. β-actin was used as house-keeping gene.
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Figure. 21. Insulin secretion in 2D and 3D culture. (A) ELISA of glucose-response insulin
release from 2D- and 3D- induced pancreatic cells exposed to 5.5 mM, 15 mM, and 25 mM
glucose. (B) Flow cytometric analysis was performed using anti-human insulin antibodies with
hESCs-induced pancreatic cells at the end of stage IV in 2D and 3D collagen/Matrigel scaffold.
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Figure. 22. Transmission electron microscopic examinzation of insulin secretory granules in
hESCs-differentiated pancreatic cells seed in 2D (A) and collagen/Matrigel scaffold (B). Scale
bar = 2µm.
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